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SKIN SYMPTOMS PREDICTING THE DEVELOPMENT OF ALLERGIC 
RESPIRATORY OUTCOMES AND ASTHMA IN BAKERS 
 
ABSTRACT 
 
 
Background: Recent studies have suggested that aside from the inhalational route, skin exposure 
may also play an important role in the sensitization to allergens, resulting in adverse allergic 
respiratory outcomes including asthma in workers exposed to these agents. This appears to be 
reported more commonly for low molecular weight agents such as isocyanates and some 
cleaning agents. This study investigated whether skin symptoms, in the presence or absence of 
allergic sensitization, can predict the development of allergic respiratory outcomes and asthma in 
bakery workers. 
 
 
Methods: A cohort study investigated 263 bakery workers using a modified ECRHS 
questionnaire; immunological tests including skin prick tests for common local aeroallergens 
(ALK-Abello´ A/S, Horsholm, Denmark), Phadiatop and serum-specific IgE to bakery allergens 
(wheat, rye and fungal α-amylase); and pulmonological tests including spirometry, non-specific 
bronchial hyperresponsiveness, and fractional exhaled nitric oxide (FeNO), after a 4 year period. 
 
 
Results: Workers’ median age was 32 years (IQR: 26-38), 50% were female, 54% were ever 
smokers and 32% were atopic. At baseline, 26% of workers were sensitized to bakery allergens, 
skin symptoms were present in 22% and 11% reported work-related skin symptoms (WRSS). 
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While the incidence of general upper (19%) and lower (22%) respiratory symptoms over the 
follow-up period were very similar, work-related upper (29%) respiratory symptoms were higher 
than lower (20%) respiratory symptoms. However, the incidence of allergic sensitization to 
bakery allergens was only 8% and a new asthma diagnosis present in 4% over this period. In 
multivariate adjusted (gender, atopy and smoking status) regression models, having a history of 
skin symptoms was associated with an increased risk of developing work-related lower 
respiratory symptoms - WRLRS (RR=2.2, 95% CI: 1.03-4.83), while having clinically 
significant symptoms of eczema or urticaria was associated with an increased risk of reporting 
general upper respiratory symptoms (RR=5.5, 95% CI: 1.30-24.20) as well as WRLRS (RR= 4.8, 
95% CI: 1.60-14.40). Furthermore, WRSS was associated with an increased risk of general upper 
respiratory symptoms (RR=5.1, 95% CI: 1.31-19.81), WRLRS (RR=4.1, 95% CI: 1.43-11.85) 
and elevated FeNO levels (FeNO>25ppb: RR=2.9, 95% CI: 1.19-7.28). The association between 
clinically significant skin symptoms or WRSS and new onset upper or lower respiratory 
symptoms were modified by use of dermal personal protective equipment. Infrequent or absent 
glove usage was associated with a higher risk (RR=5.3, 95% CI: 1.54-18.43) of having new 
onset WRLRS. 
 
 
Conclusion: Skin symptoms, more so if work-related, appear to be associated with future 
development of general and work-related upper and lower respiratory symptoms and 
inflammatory markers suggestive of asthma in bakery workers. 
 
 
Keywords: bakers, skin symptoms, asthma 
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ABREVIATIONS AND ACRONYMS 
 
APS: Aerosol Provocation System 
ACD: Allergic Contact Dermatitis 
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DF: Dermatophagoides farinae 
ECRHS: European Community Respiratory Health survey 
ERS: European Respiratory Society 
FeNO: Fractional exhaled Nitric Oxide 
FLG: Fillagrin 
FEV1: Forced Expiratory Volume in the 1st second 
IgE: Immunoglobulin E 
MDI: Methylene Diphenyl Diisocyanate 
MI: Methyl Isothiazolinone 
MRC: Medical Research Council 
OA: Occupational Asthma 
OCD: Occupational Contact Dermatitis 
OVA: Ovalbumin 
PPE: Personal Protective Equipment 
PA: Phthalic Anhydride 
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Ppb: Parts Per Billion 
RR: Risk Ratio 
SLS: Sodium Laurel Sulphate 
SPT: Skin Prick Test 
SC: Stratum Corneum 
Th2: T helper cell type 2 
TEWL: Trans-epidermal Water Loss 
TMA: Tri-mellitic Anhydride 
USA: United States of America 
WRLRS: Work-related Lower Respiratory Symptoms 
WRURS: Work-related Upper Respiratory Symptoms 
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INTRODUCTION 
 
 
Background 
 
 
Diverse immune responses have been associated with various environmental allergen exposures 
to the skin, resulting in activation of the adaptive immune response [1]. Some epidemiological 
studies and animal experiments have demonstrated positive associations between skin and 
respiratory symptoms and positive exposure-response relationships, while others have not been 
able to replicate this association [2–7]. 
 
One of the main issues highlighted by these observations has been the challenges in investigating 
skin exposure [8]. These challenges include the fact that skin exposure assessment 
methodologies are not as well developed as for inhalational exposures, and the limited exposure 
data and dermal exposure models that exist[9,10]. This is complicated further by the frequent 
variability and sporadic nature of skin exposure; the uncertainty regarding skin uptake; and the 
uncertainty that persists over the effectiveness of protective clothing in occupational settings [8]. 
Furthermore, most workers are exposed to mixtures of occupational agents, making it difficult to 
identify the specific exposure responsible for the health outcome of interest. For example, 
exposure to beryllium and isocyanates typically occurs in mixed exposure settings and these 
agents may be present in various physical or chemical forms, viz. metal particles, oxides, salts 
and alloys with copper and other metals [8]. 
 
With all the limitations for dermal exposure assessment, skin symptoms can be used as a proxy 
for skin exposure. Dermatitis in occupational settings presents with a primary lesion usually at 
Section A: Study Protocol 
3 
 
 
 
the site of contact with the causal agent, either allergic or irritant. However, when the agent is 
allergenic, secondary lesions can later flare in areas which never were in contact with the 
allergen [11]. Hence, skin symptoms implicitly suggest skin exposure and may be a route of 
sensitization and development of allergic respiratory disease including asthma. 
 
Justification 
 
 
Both high and low molecular weight contact allergens can lead to dermatological and respiratory 
health effects, such as allergic contact dermatitis, rhinitis, and asthma, causing a substantial 
health burden in occupational settings. 
 
Inhalation is an obvious route for sensitization and its pathophysiologic mechanism is well 
defined. Additionally, improvement in occupational health standards in workplaces to minimize 
allergens inhalation exposure have been put in place. Despite these measures, the incidence of 
asthma has not dropped, but remains persistently high in some of the settings where workers are 
minimally exposed to allergen inhalation, for instance, industries using isocyanates. On the other 
side, several animal studies have shown that skin may be playing an important role in the 
sensitization and development of respiratory outcomes [3,5,12–14]. Hence, further research is 
needed to ascertain skin contact as an alternative route for sensitization. 
 
The current study investigated whether skin plays a role as an entry route for sensitization to high 
molecular weight protein allergens, as it focused on skin symptoms as a predictive factor for later 
development of allergic respiratory symptoms and asthma, specifically in the bakery industry. 
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The results of the study will be used to update existing preventive measures for allergen 
exposure. 
 
Purpose and benefits 
 
 
Currently, the focus for preventing respiratory allergic disease is predominantly on the 
respiratory exposure. However, skin symptoms can be used as a proxy for skin exposure as it 
implicitly suggests skin contact as well as a likely route of exposure to allergens. Hence, 
preventive measures accounting for both routes would need to be put into place to protect high 
risk working populations in industries where allergens pose a health risk. 
 
Research questions 
 
 
1. Can initial onset of skin symptoms predict the future development of allergic respiratory 
outcomes in workers exposed to high molecular weight agents (e.g. flour allergens in 
bakers)? 
2. Are there host and/or environmental risk factors that modulate this relationship? 
 
Hypothesis 
 
 
Skin symptoms, in the absence or presence of allergic sensitization, can predict the development 
of allergic respiratory symptoms (upper and lower) and asthma in bakers. 
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Aim 
 
 
The aim of this study was to ascertain whether skin symptoms in the absence or presence of 
allergic sensitization could predict the development of allergic respiratory outcomes and asthma 
in bakers. 
 
Objectives 
 
1. To determine the prevalence of skin symptoms in the absence or presence of allergic 
sensitization in this group at baseline. 
2. To determine the presence of new-onset general or work-related respiratory 
(allergic or irritant) symptoms and asthma, among bakers after four years follow up 
among those with and without skin symptoms at baseline. 
3. To identify risk factors associated with the development of new-onset general or 
work-related respiratory (allergic or irritant) symptoms and asthma among bakers 
after four years follow up, based on the presence of skin symptoms at baseline. 
 
METHODOLOGY 
 
 
Study design 
 
This retrospective cohort study analysed a subset of data previously collected in cross sectional 
surveys in 2003 and 2007. It encompassed 517 supermarket bakery workers from 31 bakeries 
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from a supermarket chain store in the Western Cape province of South Africa. The original study 
aimed to obtain baseline data of all workers prior to any interventions being done to reduce 
sensitization to flour dust allergens in these supermarket bakeries. 
 
Study population 
 
 
For the current analysis, 329 supermarket bakery workers who participated in both the baseline 
(2003) and follow up survey (2007) and have complete records were included. 
 
Inclusion criteria: 
 
 
For purposes of this study, the following criteria were applied for inclusion in the analysis: 
 
1. Participation in the study at baseline (2003) and follow up (2007) 
 
2. Complete information on the presence/absence of skin symptoms at baseline being 
available 
3. Complete information on the sensitization status to flour allergens (IgE) at baseline and 
follow up being available 
4. Complete information on the presence/absence of respiratory outcomes of interest (doctor 
diagnosed asthma, rhinitis, respiratory symptoms) at baseline being available 
5. Spirometry (with or without bronchodilator use) or methacholine challenge test results at 
baseline being available 
6. Complete information on respiratory symptoms (general and/or work-related) at follow 
up being available 
7. Exhaled nitric oxide (FeNO) test results at follow up being available 
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Exclusion criteria: 
 
 
Workers with the following criteria were excluded from the analysis: 
 
1. Presence of doctor diagnosed asthma at baseline. 
 
2. Presence of bronchial hyperresponsiveness (based on methacholine challenge and 
positive post-bronchodilator test) at baseline. 
 
Sample size calculations 
 
 
This study analysed data from all 329 subjects who participated in both surveys in 2003 and 
2007. In this event no sample size calculation was applicable. However, since this was a 
retrospective analysis, information on the proportions of the outcome in subjects with and 
without the predictive factor was available. Hence, after applying exclusion criteria and using the 
actual proportion of asthma like symptoms in both groups, the power of the analysis was 
computed using STATA and found to be 0.69 and considered reasonable to proceed with the 
analysis. 
 
Measurements 
 
 
Data collection in the baseline and follow up, four years later, involved 517 participants from the 
main study[15] and used the following instruments: 
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a) Baseline assessment 
 
 
As per Baatjies et al.[15], the following instruments were used in the baseline: 
 
Respiratory health Questionnaire 
 
The baseline questionnaire used was the standard European Community Respiratory Health 
Survey (ECRHS) questionnaire [16] with additional questions. It gathered information on 
demographic features, skin and respiratory symptoms, other allergic conditions, smoking status, 
domestic flour dust exposures (practice and frequency of baking activities in the home), health 
and safety education and training, and degrees of exposure to flour dust during previous and 
current employment. Occurrence of skin symptoms (“itchy/scratchy skin”, “hives (”bommels”)”, 
“dry, scaly skin”, “redness of the skin”, “blisters or weeping skin”, ”burning skin”), its 
distribution (“hands/forearms” or “whole body”) and its frequency in the last year were 
investigated for both the work and domestic environments. The presence of work-related skin 
symptoms, hands/fingers trauma at work and the frequency of hand washing were also assessed. 
Categorization of smoking status included the following groups: never-smokers (lifelong 
abstinence), ex-smokers (defined as having quit completely 1 month prior to the survey), ever 
smokers and current smoker. Upper and lower airway symptoms were deemed to be work-related 
if they were reported to worsen during the work shift and improve when away from work. The 
questionnaire was administered in English or in the language of the worker where appropriate. 
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Skin prick tests 
 
Skin prick tests (SPT) were performed using the following standard common local aeroallergens 
(ALK-Abello´ A/S, Horsholm, Denmark): house dust mite (Dermatophagoides pteronyssinus), 
bermuda grass (Cynodon dactylon), rye grass (Lolium perenne), grass mix (Pollen III: Avena, 
Hordeum,Triticum, Secale), cockroach (Blattella germanica), cat (Felis domesticus), dog (Canis 
familiaris), mould mix (Cladosporium herbarum, Alternaria lternata, Fusarium) and Aspergillus 
(Aspergillus fumigatus). A positive SPT was regarded as a wheal read 15 min after testing that 
had a diameter (mean of two perpendicular measures) of 3 mm or more than the negative control. 
Areas of wheal were traced on clear tape and stored for later measurement. For the purposes of 
our study, atopy was considered to be present if the SPT to one or more common aeroallergens 
was positive. The presence of atopy in workers who did not undergo SPTs (n510) was defined by 
a positive Phadiatop1 test (ImmunoCAP 100 System; Phadia, Uppsala, Sweden). 
 
Allergen-specific immunoglobulin E 
 
Serum-specific immunoglobulin E (IgE) levels to flour dust allergens were measured in 424 
workers. Quantification of specific IgE antibodies to wheat (f4), rye (f5) and fungal α-amylase 
(k87) was performed using CAP-FEIA (fluorescence enzyme immunoassay) according to the 
manufacturer’s instructions (Phadia). An ImmunoCAP result of >0.35 kU/L was regarded as 
positive. 
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Spirometry 
 
Spirometry was performed using the Jaeger Aerosol Provocation System (APS) Pro apparatus 
according to American Thoracic Society/European Respiratory Society guidelines [17]. Workers 
were required to refrain from smoking for 1 hour, from using short-acting b2-agonist 
bronchodilators for 4 hours, and from using oral asthma medications for 8 hours prior to lung 
function testing. None were on long-acting bronchodilators. 
 
Methacholine challenge test 
 
Methacholine challenge testing was performed on all workers by trained technologists according 
to an abbreviated protocol used in epidemiological surveys. The Medic Aid Pro Nebulizer 
dosimeter method involved a protocol of increasing numbers of breaths to achieve pre-defined 
cumulative doses of methacholine [18]. The doses were delivered by the Jaeger APS MedicAid 
Side Stream APS-Nebulizer (Sensormedics, CA, USA) according to the manufacturer’s 
instructions, commencing with the lowest dose of 0.026 mg and a maximum of 0.4 mg. In 
subjects in whom PD20 methacholine was contraindicated, such as those with acute asthma 
symptoms or a baseline FEV1 <1.5 L or FEV1 <70% predicted, a bronchodilator (400 mg 
salbutamol dose) was administered instead. A change in FEV1 of >12% 10 min after 
administration of bronchodilator was considered suggestive of bronchial hyperresponsiveness. 
 
b) Follow up assessment 
 
According to Baatjies et al. [15] the following instruments were used to collect data on workers 
for the follow up assessment: 
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Respiratory health questionnaire 
 
All workers responded to the questionnaire, which collected information on demographics, 
general and work-related respiratory symptoms and several factors influencing FeNO levels, viz. 
smoking status, alcohol consumption, current medication, recent nitrate-containing food-intake 
(green vegetables), physical activity and lung function test. 
 
Fractional exhaled nitric oxide (FeNO) test 
 
A hand-held portable nitric oxide sampling device (NIOX MINO) was used to determine FeNO 
during the work shift in all workers. It was performed in a room distant from the bakery area 
during the work shift throughout the working week according to American Thoracic Society 
(European Community Respiratory Health survey)/European Respiratory Society (ERS) 
recommendations [19,20]. The testing of workers had no particular variation with regard to time 
of  testing for the different  jobs. The average of  three technically adequate FeNO 
measurements was determined. Workers were instructed to abstain from smoking, eating or 
drinking at least one hour before the test. This was confirmed prior to testing, and those who did 
not follow the instructions were tested at a later stage after ensuring their full compliance with 
these instructions. A FeNO levels >50ppb was considered to indicate the presence of allergic 
airway inflammation, while levels from 25 to 50ppb considered to be elevated [19]. 
 
DATA MANAGEMENT AND ANALYSIS 
 
 
In the data analysis, the following variables were studied in detail. 
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List and definition of variables 
 
 
Table 1 below depicts the information that was studied at baseline and at 4 years follow up in 
order to generate the predictor and outcome variables and investigated the possible risk factors 
associated with the outcomes. 
Table 1. Predictor and outcome variables 
 
 
Baseline data (2003) Outcome data at follow up (2007) 
Questionnaire: 
- Doctor diagnosed asthma and/or rhinitis 
- Respiratory symptoms 
- Skin symptoms (pattern and distribution) 
 
 
Immunological tests: 
- Specific IgE to wheat/rye/alpha-amylase 
- Skin prick test/Phadiatop for atopy 
Pulmonary function tests: 
- Spirometry 
- NSBH (from methacholine challenge and positive post- 
bronchodilator test) 
 
Risk factors: 
- Host: age, gender, atopy, smoking, childhood eczema, 
pre-existing skin disease, trauma, hand washing activities 
- Environmental: employment/job duration, job type, 
personal protective equipment use 
Questionnaire: 
Newly diagnosed asthma and/or rhinitis 
Respiratory symptoms (upper and lower) 
-Work-related 
-General 
 
 
Immunological tests: 
Specific IgE to wheat/rye/ α-amylase 
 
 
Pulmonary function: 
Exhaled nitric oxide (FeNO) 
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Predictor variables 
 
The main predictor variables pertained to the presence of: 
 
Skin symptoms in terms of: 
 
o Clinical features 
 
- Itchy/scratchy skin 
 
- Hives (” bommels”) 
 
- Dry, scaly skin 
 
- Redness of the skin 
 
- Blisters or weeping skin 
 
- Burning skin 
 
- Skin trauma (bruised, burnt or injured) 
 
- Composite skin variable (presence of itchy/scratchy skin, or hives -“bommels” or redness of 
skin) 
 
o Distribution 
 
- Forearms/hands 
 
- Whole body 
 
Allergic sensitization (elevated IgE of >0.35 KU/L to flour allergens: wheat, rye or α-amylase) 
Atopy (SPT to one or more common aeroallergens was positive. The presence of atopy in workers 
who did not undergo SPTs was defined by a positive Phadiatop test, ImmunoCAP 100 System; 
Phadia, Uppsala, Sweden). 
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Outcome variables 
 
The following outcome variables were generated using the primary data as outlined above to 
investigate the outcomes of interest: 
 
- Newly self-reported asthma 
 
- Newly prescribed treatment for asthma 
 
- Newly prescribed treatment for rhinitis 
 
- New-onset of two or more lower respiratory symptoms 
 
- New-onset of work-related lower respiratory symptoms 
 
- Newly self-reported rhinitis 
 
- Newly reported work-related rhinitis 
 
- Presence of high FeNO (>50ppb) – allergic airway inflammation 
 
- Sensitization to any flour dust allergen (wheat/rye/α-amylase) 
 
 
Data Analysis 
 
 
STATA V.14 computer software (StataCorp, College Station, Texas, USA) was used to analyse 
the respiratory health questionnaires, immunological tests (skin prick tests and serum-specific 
immunoglobulin E for flour allergens), pulmonary function tests and fractional exhaled nitric 
oxide (FeNO). Association between skin symptoms and sensitization at baseline and subsequent 
development of allergic respiratory outcomes was investigated. The associations of interest were 
investigated in two groups (Figure 1): workers who reported skin symptoms and those without 
symptoms at baseline. The group with skin symptoms was further categorised into workers with 
and without sensitization. 
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Figure 1. Flowchart for assessment of skin as a predictor of allergic respiratory outcomes 
 
 
 
At follow up, information about allergic respiratory symptoms, specific IgE to flour dust 
allergens (wheat/rye/α-amylase) and abnormal FeNO results were analyzed to calculate the 
incidence of work-related and general new-onset allergic respiratory symptoms (upper and 
lower) and asthma. Bivariate analysis and multivariate logistic regression, were used to 
investigate associations between the predictor variables and the outcomes and to identify 
possible risk factors modulating the relationship. 
 
Due to the fact that this study was based on secondary data analysis, one of the potential 
limitations was lack of power to identify real effect, as the sample size was predetermined. Other 
limitation was the healthy worker effect. There is a trend for workers who develop occupational 
disease to leave their jobs. Hence, in this cohort, it is possible that workers who developed new- 
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onset allergic respiratory outcomes and asthma may have left their employment. This could give 
the false impression that the active force is healthier than it actually is, leading to biased 
estimates. In this case, since loss to follow-up would have most likely be differential with respect 
to disease status (allergic respiratory outcomes), the measure of effect (Risk Ratio-RR) could 
have declined in magnitude. 
 
ETHICS AND COMMUNICATION 
 
 
This study involved secondary data analysis and no additional data was collected. Hence, there 
was no additional risk for original study participants. The original study was approved by the 
Research Ethics Committee of the University of Cape Town (reference no. 272/2002). The 
Declaration of Helsinki principles [21] were applied to the study: 
 
Autonomy 
 
 
The participants in the original study were informed about it being a voluntary study in terms of 
participation in the interviews, tests (skin, blood and pulmonary function) and the right to leave 
the study at any point in time. Moreover, all participants signed written informed consent. 
 
Confidentiality 
 
 
The data was recorded by patient number and the original patient records were not made 
available to the investigators. Hence, researchers were blinded regarding individual participant 
identity. 
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Beneficence 
 
 
At the time of the original study at both time points, patients were given all test results with their 
respective interpretation (if not acknowledged otherwise) and advised to show the results to their 
doctor if any problems were identified. This supplementary analysis did not directly benefit the 
participants directly. However, the findings will eventually contribute to awareness and better 
working conditions and improved medical surveillance of at risk workers. 
 
Non-maleficence 
 
 
The original study presented some low risk (discomfort) due to invasive and non-invasive 
procedures performed (blood sample collection, skin prick test and pulmonary function and 
challenge tests). However, the possible risk was minimized by means of pre-test screening and 
the procedures took place under controlled conditions (with skilled medical personnel for any 
possible emergencies). Participants gave informed consent and no adverse events were finally 
reported in this study. For the present analysis, there was no additional risk for participants since 
access to them was not required. 
 
Justice 
 
 
This study was done on bakers who are a high-risk group of workers for allergic sensitization. I 
is envisaged that the findings of the study would lead to improvement of preventive measures 
accounting for both routes of exposure to allergens, inhalation and skin contact, which ultimately 
could lower the risk of occupational allergic disease in this group of workers. 
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Dissemination of research results 
 
 
The analysis was performed for purposes of completion of the MMed degree and results will be 
disseminated through the MMed dissertation, a peer-reviewed publication in an appropriate 
journal and research forums. 
 
Funding 
 
 
Funding support for the original study was provided by research grants from the Medical 
Research Council of South Africa (Cape Town), National Research Foundation (Pretoria), 
Fogarty International Centre (Bethesda, MD, USA), the Allergy Society of South Africa (Cape 
Town) and University of Cape Town Research Committee (Cape Town) and the baking industry 
(Cape Town). 
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SKIN EXPOSURE, SYMPTOMS AND ASTHMA IN OCCUPATIONAL SETTINGS – IS 
THERE A LINK? 
 
ABSTRACT 
 
Occupational contact with allergens through the dermatological and respiratory route can lead to 
various health effects, including allergic contact dermatitis, urticaria, rhinitis and asthma, which 
may result in a substantial disease burden in occupational settings. Inhalation is an obvious route 
for sensitization and its pathophysiologic mechanisms are relatively better defined. Recent 
studies have suggested that skin exposure may also play an important role in the sensitization 
and development of respiratory outcomes in exposed workers. The review found that the 
evidence for such an association was limited and the immune mechanisms not well understood. 
A better understanding of this association is required, more so for high molecular weight 
(protein) agents since the evidence is more scant in the literature, so as to identify important risk 
factors that may contribute towards existing preventive efforts in reducing the incidence of 
allergy and asthma in occupational settings. 
 
INTRODUCTION 
 
Diverse immune responses have been associated with various environmental allergen exposures 
to the skin, resulting in activation of the adaptive immune response [1]. In barrier-disrupted skin, 
type 2 lymphoid cells, mast cells and basophils are known to trigger pathogenic Th2 responses in 
murine models [2]. However, even when the skin barrier is intact; it still has properties that may 
allow, to some extent, permeability to some allergens. The “brick and mortar” model, a 
schematic explanation of the permeability of the stratum corneum, in which corneocytes are the 
bricks and the lipids are the mortar, presents the stratum corneum as a metabolically active 
structure with adaptive functions. This could be behind the mechanism in which some allergens 
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could be absorbed by an healthy skin [3]. 
Some epidemiological studies and animal experiments have demonstrated positive associations 
between skin and respiratory symptoms and positive exposure-response relationships, while 
others have not been able to replicate this [4–9]. 
 
One of the main issues highlighted by these observations has been the challenges in investigating 
skin exposure [10]. Methodologies to assess skin exposure are not as well advanced as for 
inhalational assessment and there is limited exposure data [11,12]. Additionally, airborne 
exposure to skin is variable and sporadic and there is uncertainty regarding the extent of skin 
uptake [10]. Furthermore, most workers are exposed to mixtures of occupational agents, making 
it difficult to identify the specific exposure responsible for the health outcome of interest. For 
example, exposure to beryllium and isocyanates typically occurs in mixed exposure settings and 
these agents may be present in various physical or chemical forms, viz. metal particles, oxides, 
salts and alloys with copper and other metals [10]. 
 
The main objective of this literature review was to assess the nature and extent of the 
associations between skin and respiratory symptoms following skin exposure to high and low 
molecular weight sensitizers. The review included all relevant English publications that were 
retrieved from PubMed/Medline and Google Scholar. The key search terms that were used in this 
review were terms used in other reviews and included “skin”, “asthma” OR “dermal” AND “high 
molecular weight” OR “low molecular weight” AND “sensitization” OR “dose-response” OR 
“link”. Other terms that were subsequently added included: allergen, allergy, atopy, occupational, 
work- related, respiratory, dermatological, dermatitis. Furthermore, some articles were retrieved 
using the functions “similar articles search” in PubMed and “related articles” in Google Scholar 
as well relevant articles that were cited in the references of these articles. 
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EPIDEMIOLOGICAL STUDIES 
 
Co-existing or sequential development of dermal and respiratory outcomes 
 
Workers in various occupations report both skin and respiratory symptoms. Table 1illustrates 
case study reports in which both dermal and respiratory outcomes, (diagnosed using patch tests 
and inhalation challenge tests, respectively) were observed in occupational settings with diverse 
exposures. These allergens can cause both occupational asthma (OA) as well as allergic contact 
dermatitis (ACD) [13]. To ascertain which health outcome precedes the other can be a challenge 
due to the nature of the study design used and the lack of a comparison group in such reports. 
 
Arrandale [4] conducted an analysis of four cross-sectional pooled studies from a soda ash plant, 
softwood planing mill, embalming and cabinet making, in which workers were exposed to 
ammonia, softwood dust, formaldehyde and/or glutaraldehyde and hardwood dust, respectively. 
Altogether, both skin and respiratory symptoms were reported by 11% (26/236). The highest 
prevalence of both dermal and respiratory symptoms was seen among embalmers, with no 
statistical significance. Although this study does not show temporality, it reinforces evidence of 
co-occurrence of both respiratory and dermal symptoms in occupational settings [4]. Similarly, 
previous studies among sewage treatment and isocyanate workers reported concomitant 
occurrence of dermal and respiratory symptoms in exposed workers [14,15]. However, Bauer et 
al. [16] could not stablish correlation between occupational hand dermatitis and flexural 
dermatitis, respiratory atopy (allergic rhinitis and bronchial asthma), serum IgE ±100IU/ml or 
metal sensitization in their study in bakers. 
 
Aside from the need to identify temporality, the co-existence of dermal and respiratory 
symptoms does not necessarily indicate that the same exposure is the trigger for both outcomes, 
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unless the exposure assessment specifically characterised the nature and route of the exposures in 
affected workers [13]. 
Table 1. Co-occurring occupational asthma (OA) and occupational contact dermatitis 
(OCD) – diagnosed using specific inhalation challenge and patch testing – case reports 
reported 
 
Exposure 
 
Occupation 
 
Author (year) 
 
2-hydroxyethyl methacrylate (HEMA) 
 
Beautician 
 
Moulin et al., 2009 
 
Diglycidyl Ether of Bisphenol A 
(DGEBA) 
 
Resin applier 
 
Moulin et al., 2009 
 
Diphenylmethane-4,4’- diisocyanate 
(MDI) 
 
Manufacturing (Automotive Industry) 
 
Valks et al., 2003 
 
Potassium Dichromate 
 
Cement Floorer 
 
De Raeve et al., 1998 
 
Aziridine Hardener 
 
Painter and varnisher 
 
Kanerva et al., 1995 
 
Onion 
 
Homemaker 
 
Valdivieso et al., 1994 
 
Nickel 
 
Manual grinding of metal castings 
 
Estlander et al., 1993 
Spiramycin Poultry breeder 
Paggiaro et al., 1979 
Reproduced from Arrandale 2012 [13] 
 
Association between skin exposure, allergy specific sensitization and subsequent 
development of respiratory disease 
 
Table 2 summarises the few key epidemiological studies that have investigated the role of skin 
exposure and symptoms and the subsequent development of respiratory symptoms including 
asthma in these workers. 
 
Brisman et al. [16] have alluded to the association between bakers’ asthma and eczema, without 
indicating whether sensitization to wheat flour was due to inhalation or due to contact with 
allergens through the skin (or both). In a study of bakers and auto body shop workers 
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(ABSWs) exposed to wheat and isocyanates respectively, Arrandale et al. [5] reported an 
association between skin and respiratory symptoms. Work-related itchy skin was associated with 
wheeze, asthma-like symptoms and work-related asthma symptoms in ABSWs but not bakers. 
The authors did, however, indicate, that the body shop workers had adhered to much stricter use 
of personal protective equipment, while such use of personal protective equipment had not been 
observed by the bakers [5]. A previous study by Arrandale et al. [4] also found that eczema 
increases the odds of concurrent work-related skin and respiratory symptoms [4]. It needs to be 
borne in mind that this not necessarily indicate that skin exposure is always predictive of 
respiratory outcomes. 
 
Lynde et al. [18] investigated a group of predominantly male (84%) professional cleaners with 
9.3% having a current rash and 18.6% reporting a rash in the last 12 months. The study found 
that cleaners with a current rash and those reporting a rash in the last twelve months were at 
significantly increased odds of reporting work-related respiratory symptoms compared to those 
without a rash. This suggested an association between the presence of work-related asthma 
symptoms and dermatitis among professional cleaners [18]. However, atopy was considered as a 
possible underlying mechanism for this association, and lack of PPE use could have also been 
another factor influencing this association [18]. 
 
Isocyanates, used in spray-painting and polyurethane foam products, have received considerable 
attention in relation to skin exposure and the resulting effects of asthma [5,7,10,20-21]. A key 
link for suggesting an association between allergic sensitization via transcutaneous route for 
isocyanates and asthma has been the improvement in occupational health standards in 
workplaces due to the use of respirators to prevent isocyanate inhalation. However, the incidence 
of isocyanate-induced asthma remains persistently high, particularly in settings where skin- 
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contact with isocyanates has not been well controlled [20]. A laboratory study by Karol et al. 
 
[22] reported that isocyanate exposure to the skin, particularly TDI, could induce pulmonary 
hypersensitivity in guinea pigs. Subsequent studies have shown that similar patterns of 
sensitization exist in humans [1,5,7]. 
 
Table 2. Studies of working populations investigating the association between skin 
exposure/symptoms and respiratory symptoms/asthma 
Author & 
year 
Arrandale et al., 
2013 [5] 
Arrandale et al., 
2012 [4] 
Lynde et al., 2009 
[18] 
Petsonk et al., 
2000 [22] 
Aim of study To investigate 
associations between 
skin and respiratory 
symptoms in bakery 
and auto body shop 
workers (ABSW) 
To identify predictors 
of reporting 
concurrent skin and 
respiratory symptoms 
in a clinical 
population 
To compare the 
prevalence of 
occupational 
cutaneous symptoms 
among professional 
indoor cleaners to 
other building 
workers (OBW) and 
their association with 
exposures and 
respiratory symptoms 
To evaluate the 
respiratory health of 
workers exposed to 
Methylene 
Diphenyl 
Diisocyanate (MDI) 
Study 
design 
Cross-sectional Cross-sectional Cross-sectional Cohort 
Population 723 bakers 
473 ABSW 
204 patients from the 
occupational health 
clinic 
549 professional 
cleaners 
593 OBW 
214 wood product 
plant employees 
(144 completed 
initial, follow-up 
and occupational 
questionnaires) 
Agent Isocyanate and Wheat Multiple agents 
(animal dander, 
cement, isocyanates, 
pesticides, wet work, 
, dust, fumes, paint) 
Cleaning agents MDI 
Assessment 
tool/s 
Questionnaire, IgE 
for common 
inhalants, 
specific challenge 
tests and personal 
airborne exposure 
measurements 
Questionnaire Questionnaire Questionnaire, 
serial peak flow, 
spirometry, 
methacholine 
challenge, specific 
IgE 
Skin 
symptoms 
prevalence 
(%) 
Work-related itchy 
skin: 
ABSW - 9%; Bakers 
- 17% 
Possible work-related 
skin disease: 82% 
Current rash: cleaners 
- 10%, OBW 6% 
Not reported 
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Author & 
year 
Arrandale et al., 
2013 [5] 
Arrandale et al., 
2012 [4] 
Lynde et al., 2009 
[18] 
Petsonk et al., 
2000 [22] 
   Rash in the past 12 
months: cleaners - 
19%, OBW 16% 
 
Respiratory 
symptom 
prevalence 
(%) 
Work-related asthma 
symptoms (WRAS): 
ABSW - 4%; Bakers 
- 2% 
Possible work-related 
respiratory disease: 
18% 
In males with rash: 
• physician- 
diagnosed asthma - 
19% 
• new onset asthma 
14% 
• ≥3 respiratory 
symptoms: 77% 
• ≥2 WRAS: 63% 
• ≥3 WRAS: 40% 
Among the 178 
(who participated in 
at least 1 follow-up 
survey): 
• initial asthma-like 
symptoms - 11% 
• follow-up 
asthma-like 
symptoms - 20% 
• new-onset 
asthma-like 
symptoms - 12% 
Association 
between 
skin 
exposure/ 
symptoms 
and 
respiratory 
symptoms/ 
asthma 
Association between 
work-related itchy 
skin and respiratory 
symptoms in: 
ABSW: 
• Wheeze OR= 2.50 
(95% CI 1.7–3.6) 
Asthma like 
symptoms 
OR=2.12 (95% CI 
1.5–3.0) 
• WR asthma 
symptoms 
OR=3.61 (95% CI 
1.4–9.4) 
Bakers: 
• Wheeze OR=1.60 
(95% CI 1.1–2.3) 
• Asthma like 
symptoms 
OR=1.54 (95% CI 
1.2–2.0) 
• WR asthma 
symptoms 
OR=2.15 (95% CI 
0.7–6.3) 
Exposure-response 
relationship in 
ABSW 
Eczema increases 
odds of concurrent 
work-related skin and 
respiratory 
symptoms: OR=3.68 
(95% CI: 1.7–7.8) 
Rash in the past 12 
months associated 
with: 
• Physician 
diagnosed asthma 
OR=2.3 (95% CI: 
1.1–4.5) 
• New onset asthma 
OR=3.0 (95% CI: 
1.2–7.6) 
• ≥3 respiratory 
symptoms OR=2.6 
(95% CI: 1.6–4.3) 
• ≥2 WRAS OR=3.2 
(95% CI: 1.9–5.3) 
• ≥3 WRAS OR=4.0 
(95% CI: 0 2.2– 
7.2) 
52% of workers 
who reported MDI 
skin stains reported 
asthma-like 
symptoms 
Section B: Literature Review 
30 
 
 
 
Author & 
year 
Arrandale et al., 
2013 [5] 
Arrandale et al., 
2012 [4] 
Lynde et al., 2009 
[18] 
Petsonk et al., 
2000 [22] 
 • itchy/dry skin 
PR=1.55, 95 % CI: 
1.2–2.0 
• work-related itchy 
skin PR= 1.97 (95 
% CI 1.2–3.3) 
   
Study 
limitations 
• poor correlation 
between airborne 
and skin exposure 
for particulates 
• lack of information 
on other, 
potentially causal, 
exposures in the 
workplace 
• potential role of 
Type IV allergy or 
irritant mechanisms 
in symptom 
development not 
modelled 
• healthy worker 
effect due to fewer 
symptomatic 
subjects at higher 
exposure levels 
• cross-sectional 
study – temporality 
cannot be 
ascertained 
• not generalizable to 
all workers due to 
the selective 
clinical population 
• low response rate 
• outcomes (rashes) 
were self-reported 
and not clinically 
confirmed 
• loss to follow up 
• lack of 
environmental 
exposure 
measurements f 
 
 
 
 
PATHOPHYSIOLOGICAL CORRELATES 
 
 
Several studies in children have suggested that skin exposure and sensitization precede the 
response in the airways. Dohi et al. [24] compared eight atopic dermatitis (AD) patients without 
previous report of asthma symptoms, and 8 mite-allergic asthmatic patients. These 2 groups were 
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subjected to bronchial inhalation challenges (non-specific with methacholine and specific with 
house dust mite). Results demonstrated that both IgE and anti-mite IgE antibody were higher in 
AD patients than mite-allergic asthmatic patients [24]. The response for methacholine in AD 
patients was from normal to asthmatic range. In a study by Lack et al. [25], peanut allergy did 
not show dependent association with intake of soymilk and soy formula. Peanut allergy was 
however associated with skin rash over the joints and flexures, crusted skin rash, and intake of 
soy milk and soy formula. In addition, use of peanut containing oils on the skin were associated 
with peanut allergy, suggesting that skin exposure could lead to generalised sensitization [25]. In 
more severe form, local skin contact with certain foods, medications, latex, metals and 
occupational allergens may result in generalised urticaria or systemic symptoms (angioedema, 
wheezing) [26]. 
 
It has also been suggested that beryllium sensitization in those suffering from chronic beryllium 
lung disease (CBD), may also have percutaneous origins. Tinkle et al. [27] observed that 
decreasing inhalational exposure had no effect on the incidence of the disease, suggesting that 
inhalation was not the only cause for the disease. The investigators suggested that following skin 
exposure to beryllium, the inhalational exposure to beryllium necessary to elicit an immune 
response and the formation of a CBD-related granuloma, was significantly reduced. In further 
support of this hypothesis, topical application of beryllium ointment to C3H/HeJ Heston mice 
showed an increase in beryllium sensitivity in the mice as determined through beryllium 
lymphocyte proliferation tests of lymph node and peripheral blood [27]. Furthermore, it has been 
shown that the stratum corneum (SC), the external layer of the skin, which although 
mechanically strong and resilient to stress and physical strain, may be penetrated by fine and 
ultra-fine beryllium particles [27]. 
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The most refined models demonstrating the link between allergic sensitization and asthma from 
skin exposure, has been from murine experimental studies. Spergel et al. [28] applied the high- 
molecular weight molecule ovalbumin (OVA) via occlusive patch tests to tape stripped mice 
skin. This experiment showed an OVA epicutaneous sensitization and local allergic dermatitis. 
Later, when the sensitized mice was exposed to intravenous methacholine, the response was 
eosinophilia in the bronchoalveolar lavage fluid and airway hyperresponsiveness [28]. 
 
In murine models, it has also been demonstrated that dermal infiltration of eosinophils in 
response to dust mite allergens in skin that has been sensitized by barrier disruption is greater 
than sensitization through intact skin [28–31]. This suggests that there is a higher induction of 
Th2-dominant immunologic responses to environmental allergens through skin that has the skin 
barrier disrupted, as is experienced in patients with atopic dermatitis [32], and particularly 
following rubbing or scratching of skin, compared to intact skin. There is common agreement for 
Th2 response, that allergen exposure requires both the involvement of barrier disruption and an 
adaptive immune recognition in order to induce an allergic response [1,33]. 
 
PREDISPOSING FACTORS FOR ALLERGIC RESPIRATORY SYMPTOMS 
FOLLOWING SKIN EXPOSURE 
 
Several predisposing risk factors could result in sensitization and to the subsequent development 
of allergic respiratory symptoms following skin exposure to occupational and environmental 
allergens. 
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Host risk factors 
 
 
Pre-existing skin diseases 
 
 
Atopic Dermatitis 
 
The integrity of the skin barrier is intrinsic to an individual’s ability to respond to dermal 
allergen exposure [34]. In AD both cellular immune abnormalities and skin barrier defects are 
known to be behind its pathophysiologic mechanism [35]. Various non-invasive biomarkers of 
epidermal permeability are used to identify increased risk for allergic sensitization through the 
skin. Trans-epidermal water loss (TEWL) has been directly, but not exclusively, associated with 
atopic dermatitis and the associated risk of respiratory allergy [36]. Kelleher et al. [37] found that 
new-borns with raised TEWL were at increased risk of developing atopic dermatitis at one year 
of age, as well as IgE associated food allergies, despite the absence of early-onset atopic 
dermatitis. Loo et al. [38] also demonstrated that children with eczema before 18 months 
exposed to inhalant allergen (house dust mite) were more likely to present with positive skin 
prick tests at 18 months [38]. 
 
Irritant Dermatitis 
 
 
A damaged skin barrier, as is present in irritant dermatitis due to either physical, chemical or 
biological processes, is a potential route of entry for allergens [13]. Nielsen [39] demonstrated 
that skin treated with higher concentrations of sodium laurel sulphate (SLS), a known skin 
irritant, had greater overall penetration and a greater rate of penetration of chemical substances 
(pesticides with a wide range of solubility) compared of with undamaged skin [39]. 
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Ichthyosis vulgaris 
 
 
Bremmer et al. [34] demonstrated in a study of 491 patients with atopic dermatitis and ichthyosis 
vulgaris (IV) that those with higher severity of IV were more likely to report asthma, even after 
adjusting for atopic dermatitis severity, age, sex, and season of symptoms occurrence. He 
suggested that the presence of severe IV could be used as a marker for patients having a greater 
likelihood of developing allergic respiratory disease [34]. 
 
Trauma 
 
 
Skin trauma is another risk factor for facilitating entry of contact allergens into the body. This 
may increase a person’s risk of sensitization as has been observed in, for instance, seafood 
processing workers and animal handling workers (rats) resulting in the development of allergic 
respiratory symptoms [7,10,40]. 
 
Filaggrin gene mutations 
 
 
One of the first-line factors associated with skin-barrier deficiencies are Filaggrin (FLG) defects 
[41], which typically occur due to inherent FLG gene mutations [42]. FLG is an important 
protein responsible for the strength and integrity of the SC, regulating the permeability of the 
skin to water and antigens, involved with the packing of keratin filaments in the epidermis, and 
maintaining the skin’s normal acid pH. [1] Studies in the general population evaluating allergen 
exposure via skin, sensitization and respiratory outcomes have been reported [42–44]. Brough et 
al. [45] reported a positive association between FLG defects and peanut allergy. Filaggrin defects 
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have also been identified in atopic dermatitis patients, and there appears to be a correlation 
between the extent of FLG defects, the extent of allergen exposure through the skin, and the 
severity of atopic dermatitis [45]. It was reported that 50% of patients (in European and Asian 
populations) with moderate-to-severe atopic dermatitis have loss-of-function mutations in the 
gene encoding FLG. Additionally, these patients were reported to have an increased the risk of 
developing inhalant allergic sensitization, allergic rhinitis, asthma, and peanut allergy. In 
African-American populations this defect is rare [45,46]. 
 
Environmental risk factors 
 
 
Various high molecular weight (generally proteins) and low molecular weight (generally 
chemicals) allergens are capable of stimulating the induction of IgE antibodies and result in 
sensitization and the development of allergic respiratory symptoms [7]. The extent to which they 
are able to do so will depend on the agent’s physical properties, exposure intensity and duration. 
 
Agent 
 
 
Physical properties 
 
 
Theoretically, liquid and solid allergens will facilitate skin contact and entry when compared to 
aerosolised substances. Petsonk et al. [23] found that after 2 years of working in a wood 
manufacturing plant, subjects who worked with liquid methylene diphenyl diisocyanate (MDI) 
had a relatively higher odd of reporting asthma-like symptoms than those who did not work with 
liquid MDI. Additionally, those who reported observing MDI skin stains at least once 
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(suggesting skin exposure) also had higher odds of reporting asthma-like symptoms compared to 
those who never observed such stains. However, the prevalence of asthma-like symptoms was 
more prevalent among workers who reported brief removal of respiratory personal protective 
equipment (PPE) while performing their routine tasks that included liquid MDI handling. The 
investigators concluded that although inhalation was an important route of exposure for 
development of the respiratory symptoms, skin exposure may have also played a role in these 
outcomes.  
 
Chemical properties (molecular structure) 
Transcutaneous chemical penetration also depends on chemical characteristics of agents. 
Haptens must be structurally able to bind with a protein as a pre-requisite to be recognized by the 
immune system. [39] While lipophilic properties facilitate skin permeability for allergens, [39] 
hydrophilic properties are also needed to allow for movement of the chemical from the SC into 
the dermis [47]. Hence, an efficient allergen, should be amphiphilic (both lipophilic and 
hydrophilic) [47]. Low molecular weight particles and molecules, such as nickel and poison ivy 
(urushiol) are known contact allergens that cause skin sensitization by their action of binding to 
host proteins in the skin [7]. As a result of their chemical reactivity with host proteins, these 
particles cause otherwise innocuous compounds to be converted into hapten-protein complexes 
that stimulate the adaptive immune response [1]. High molecular weight protein allergens such 
as peanut, dust mite, or water-soluble cat allergens, which range in size from 5,000 Da to 
100,000 Da, are generally unable to pass through the skin’s cutaneous permeability barrier due to 
their size [48]. In such instances, it is generally understood that sensitivity to such high 
molecular weight compounds is only possible when the integrity of the skin is to some extent 
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compromised [1]. 
 
Exposure intensity and duration (dose-response relationships) 
 
 
The concentration of the agent on the skin surface and the duration of this contact, apart from all 
other conditions that interfere with the skin integrity, may influence the body’s response to an 
allergen. Some studies in animal models have investigated trimellitic anhydride (TMA), phthalic 
anhydride (PA) and MDI and found that increasing sensitising intradermal doses did not increase 
a respiratory response. However, Arakawa et al. [49] found a dose-dependent response in guinea 
pigs for Dermatophagoides farinae (DF mite) and a dose-response relationship with increasing 
doses of intradermally administered TMA eliciting asthma-like symptoms. 
 
Devos et al. [50] investigated the asthmagenic capacity of Methylisothiazolinone (MI), a known 
cause of allergic contact dermatitis, commonly used in cosmetics, household products as well as 
in different industries, in animal models. Fifteen days after dermal administration of MI, the 
investigators did not show a significant respiratory response (either airway hyperreactivity or 
inflammation). The study concluded that while MI was a dermal sensitizer and irritant, it was 
unable to elicit an asthma-like response. Paulunh et al. [9] also investigated the dose-response 
relationship of MDI exposure in animal models and lung response after primary skin exposure. 
Surface area or dose-to-body weight did not show specific associations. On the contrary, the 
magnitude of the respiratory response was dependent on the frequency of inhalation challenge 
doses administered instead of the previous cutaneous doses. 
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CONCLUSION 
 
 
Skin is an important route of exposure to allergens leading to sensitization and the potential to 
cause allergic skin symptoms that could co-exist or precede respiratory symptoms, and other 
systemic health outcomes. There is, however, much that still needs to be investigated to better 
understand the modes of entry and sensitization in occupational settings. Particularly among 
workers exposed to high molecular weight protein allergens since the evidence for this is 
scant in the literature, there is a need to ascertain the pathophysiological mechanisms 
involved in skin exposure resulting in respiratory disease and other systemic effects. By 
addressing these issues, better interventions aimed at preventing occupational exposure to 
these allergens can be achieved. 
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SKIN SYMPTOMS PREDICTING THE DEVELOPMENT OF ALLERGIC 
RESPIRATORY OUTCOMES AND ASTHMA IN BAKERS 
Vânia Chongo-Faruk 
 
ABSTRACT 
 
 
Objective: The aim of this study was to ascertain whether skin symptoms could predict the 
development of allergic respiratory outcomes and asthma in bakers. 
 
 
Methods: A cohort study investigated 263 bakery workers using a modified ECRHS 
questionnaire; immunological tests including skin prick tests for common local aeroallergens, 
Phadiatop and serum-specific IgE to bakery allergens (wheat, rye and fungal α-amylase); and 
pulmonological tests including spirometry, non-specific bronchial hyperresponsiveness and 
fractional exhaled nitric oxide (FeNO), over a four-year period. 
 
 
Results: Workers’ median age was 32 years (IQR: 26-38), 50% were female, 54% were ever 
smokers and 32% were atopic. At baseline, 26% of workers were sensitized to bakery 
allergens, skin symptoms were present in 22% and 11% reported work-related skin symptoms 
(WRSS). While the incidence of general upper (19%) and lower (22%) respiratory symptoms 
over the follow-up period were very similar, work-related upper (29%) respiratory symptoms 
were higher than lower (20%) respiratory symptoms. However, the incidence of allergic 
sensitization to bakery allergens was only 8% and a new asthma diagnosis present in 4% over 
this period. In multivariate adjusted (gender, atopy and smoking status) regression models, 
having a history of skin symptoms was associated with an increased risk of developing work- 
related lower respiratory symptoms - WRLRS (RR=2.2, 95% CI: 1.03-4.83), while having 
clinically significant symptoms of eczema or urticaria was associated with an increased risk 
of reporting general upper respiratory symptoms (RR=5.5, 95% CI: 1.30-24.20) as well as 
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WHAT THIS PAPER ADDS 
 
1. Skin symptoms can predict further development of adverse respiratory outcomes 
in bakers. 
2. Bakers who develop work-related skin symptoms are at increased risk to further 
develop allergic airway inflammation, upper and lower respiratory symptoms. 
3. Absent or infrequent use of dermal protection increases the risk of developing 
allergic airway inflammation and chest symptoms in bakers. 
WRLRS (RR= 4.8, 95% CI: 1.60-14.40). Furthermore, WRSS was associated with an 
increased risk of general upper respiratory symptoms (RR=5.1, 95% CI: 1.31-19.81), 
WRLRS (RR=4.1, 95% CI: 1.43-11.85) and high levels of FeNO (FeNO>25ppb: RR=2.9, 
95% CI: 1.19-7.28). The association between clinically significant skin symptoms or WRSS 
and new onset upper or lower respiratory symptoms were modified by use of dermal personal 
protective equipment. Infrequent or absent glove usage was associated with a higher risk 
(RR=5.3, 95% CI: 1.54-18.43) of having new onset WRLRS. 
 
 
Conclusion: Skin symptoms, more so if work-related, appear to be associated with the 
future presence of general and work-related upper and lower respiratory symptoms and 
increased inflammatory marker levels suggestive of asthma in bakery workers. 
 
 
Keywords: bakers, skin symptoms, asthma 
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INTRODUCTION 
 
 
Occupational contact with allergens through the dermatological and respiratory route can lead 
to various health effects, including allergic contact dermatitis, urticaria, rhinitis and asthma, 
which may result in a substantial disease burden in occupational settings. Inhalation is an 
obvious route for sensitization and its pathophysiologic mechanisms are relatively better 
defined. Recent studies have suggested that skin exposure may also play an important role in 
the sensitization and development of respiratory outcomes in exposed workers. The review 
found that the evidence for such an association was limited and the immune mechanisms not 
well understood. A better understanding of this association is required, more so for high 
molecular weight (protein) agents, so as to identify important risk factors that may contribute 
towards existing preventive efforts in reducing the incidence of allergy and asthma in 
occupational settings [1]. 
 
A few epidemiological studies and animal experiments have demonstrated positive 
associations between skin and respiratory symptoms and positive exposure–response 
relationships, whereas others have not been able to replicate this association [2–7]. One of the 
main issues highlighted by these observations has been the challenges in investigating skin 
exposure [8]. Methodologies for assessing skin exposure are not as well advanced as for 
inhalational assessment, and exposure data are limited [9,10]. In addition, airborne exposure 
to skin is variable and sporadic and there is an uncertainty regarding the extent of skin uptake 
[8]. Furthermore, most workers are exposed to mixtures of occupational agents, making it 
difficult to identify the specific exposure responsible for the health outcome of interest. 
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Several host and environmental factors are implicated in the pathophysiological process of 
sensitization and further development of allergic respiratory symptoms following skin 
exposure. Host factors such as pre-existing skin diseases, namely, atopic dermatitis, irritant 
dermatitis, ichthyosis vulgaris and trauma were shown to increase the risk of sensitization 
following dermal allergen exposure[1]. Filaggrin gene mutations were also reported as a risk 
factor to develop sensitization and respiratory outcomes in studies investigating dermal 
allergen exposure [11–15]. Environmental factors such as the agent’s physical [16,17] and 
chemical properties [18–21] determine its likelihood to cross the skin barrier and to stimulate 
the induction of IgE antibodies resulting in sensitization. However, dose-response 
relationship may also have a crucial role to play in this process for some allergen agents 
[5,22,23]. 
 
In the bakery industry, very little is known regarding the role of skin exposure in the process 
of sensitization and subsequent development of respiratory disease. The aim of this study was 
to investigate whether skin symptoms in the presence or absence of allergic sensitization 
could predict the development of allergic respiratory outcomes and asthma in bakers over a 
four-year follow-up period. 
 
MATERIALS AND METHODS 
 
 
Study design, population and sampling 
 
This retrospective cohort study analyzed a subset of data previously collected in cross 
sectional surveys in 2003 and 2007. It encompassed 517 supermarket bakery workers from 31 
bakeries from a supermarket chain store in the Western Cape province of South Africa. The 
original study aimed to obtain baseline data of all workers prior to any interventions being 
done to reduce sensitization to flour dust allergens in these bakeries. The aim of the follow-up 
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study, encompassing 544 workers, was to document the emergence of newly acquired allergic 
respiratory outcomes. 
 
For the current analysis, 329 supermarket bakery workers who participated in both the 
baseline (2003) and follow up survey (2007) and had complete records were included. 
However, further analysis was performed on only 263 subjects that met inclusion criteria. 
Study exclusion criteria comprised the presence of doctor diagnosed asthma or 
NSBH/significant airway reversibility at baseline. 
 
Health outcome assessment 
 
a) Baseline assessment 
 
The following instruments were used in the baseline assessment as reported by Baatjies et al. 
[24]: 
 
Respiratory health questionnaire 
 
The standard European Community Respiratory Health Survey (ECRHS) questionnaire [25] 
with additional questions was used. It gathered information on demographic features, skin 
and respiratory symptoms, other allergic conditions, smoking status, domestic flour dust 
exposures (practice and frequency of baking activities in the home), and duration of 
employment, the bakery and job characteristics, including use of personal protective 
equipment. Occurrence of skin symptoms (“itchy/scratchy skin”, “hives” [“bommels”], “dry, 
scaly skin”, “redness of the skin”, “blisters or weeping skin”,” burning skin”), its distribution 
(“hands/forearms” or “whole body”) and its frequency in the last year were investigated for 
both the work and domestic environments. The presence of work-related skin symptoms and 
the frequency of hand washing were also assessed. Smoking status was classified into the 
following three categories: never-smoker (lifelong abstinence), ex-smoker (defined as having 
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quit completely 1 month prior to the survey) and current smoker. Upper and lower airway 
symptoms were deemed to be work-related if they were reported to worsen during the work 
shift and improve when away from work. The questionnaire was administered in English and 
in the language of the worker where appropriate. 
 
Skin prick tests 
 
Skin prick tests were performed using the following standard common local aeroallergens 
(ALK-Abello´ A/S, Horsholm, Denmark): house dust mite (Dermatophagoides 
pteronyssinus), bermuda grass (Cynodon dactylon), rye grass (Lolium perenne), grass mix 
(Pollen III: Avena, Hordeum,Triticum, Secale), cockroach (Blattella germanica), cat (Felis 
domesticus), dog (Canis familiaris), mould mix (Cladosporium herbarum, Alternaria lternata, 
Fusarium) and Aspergillus (Aspergillus fumigatus). A positive SPT was regarded as a wheal 
read 15 min after testing that had a diameter (mean of two perpendicular measures) of 3 mm 
or more than the negative control. Areas of wheal were traced on clear tape and stored for 
later measurement. For the purpose of this study, atopy was considered to be present if the 
SPT to one or more common aeroallergens was positive. The presence of atopy in workers 
who did not undergo SPTs was defined by a positive Phadiatop1 test (ImmunoCAP 100 
System; Phadia, Uppsala, Sweden). 
 
Allergen-specific immunoglobulin E 
 
Serum-specific immunoglobulin E levels to flour dust allergens were measured on all 
workers. Quantification of specific IgE antibodies to wheat (f4), rye (f5) and fungal α- 
amylase (k87) was performed using CAP-FEIA (fluorescence enzyme immunoassay) 
according to the manufacturer’s instructions (Phadia). An ImmunoCAP result of >0.35 kU/L 
was regarded as positive. 
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Spirometry 
 
Spirometry was performed using the Jaeger Aerosol Provocation System (APS) Pro apparatus 
according to American Thoracic Society/European Respiratory Society guidelines [26]. 
Workers were required to refrain from smoking for 1 hour, short-acting b2-agonist 
bronchodilators for 4 hours, and oral asthma medications for 8 hours prior to lung function 
testing. None of the workers were receiving treatment that included long-acting 
bronchodilators. 
 
Methacholine challenge test 
 
Methacholine challenge testing was performed on all workers by trained technologists 
according to an abbreviated protocol used in epidemiological surveys. The Medic Aid Pro 
Nebulizer dosimeter method involved a protocol of increasing numbers of breaths to achieve 
pre-defined cumulative doses of methacholine [27]. The doses were delivered by the Jaeger 
APS MedicAid Side Stream APS-Nebulizer (Sensormedics, CA, USA) according to the 
manufacturer’s instructions, commencing with the lowest dose of 0.026 mg and a maximum 
of 0.4 mg. In subjects in whom PD20 methacholine was contraindicated, such as those with 
acute asthma symptoms or a baseline FEV1 <1.5 L or FEV1 <70% predicted, a 
bronchodilator (400 mg salbutamol dose) was administered instead. A change in FEV1 of 
>12% 10 min after administration of the bronchodilator was considered suggestive of 
 
bronchial hyperresponsiveness. 
 
 
b) Follow up assessment 
 
According to Baatjies et al. [24] the following instruments were used to collect data on 
workers for the follow up assessment: 
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Respiratory health questionnaire 
 
An abbreviated ECRHS questionnaire, which collected information on demographics, general 
and work-related respiratory symptoms and several factors influencing FeNO levels, viz. 
smoking status, alcohol consumption, current medication, recent nitrate-containing food- 
intake (green vegetables), physical activity and lung function test. 
 
Fractional exhaled nitric oxide (FeNO) 
 
A hand-held portable nitric oxide sampling device (NIOX MINO) was used to determine 
FeNO during the work shift in all workers. It was performed in a room distant from the 
bakery area during the work shift throughout the working week according to American 
Thoracic Society (ATS) and European Respiratory Society (ERS) recommendations [28,29]. 
The testing of workers had no particular variation with regard to time of testing for the 
different jobs. The average of three technically adequate FeNO measurements was 
determined. Workers were instructed to abstain from smoking, eating or drinking at least one 
hour before the test. This was confirmed prior to testing and those who did not follow the 
instructions were tested at a later stage after ensuring their full compliance with these 
instructions. A FeNO level >50ppb was considered to indicate the presence of allergic airway 
inflammation, while levels between 25-50pbp were considered to be elevated [28]. 
 
DATA ANALYSIS 
 
 
The data was analysed using STATA V.14 computer software (StataCorp, College Station, 
Texas, USA). Descriptive statistics such as medians, interquartile ranges and proportions were 
used to summarize the data. The incidence of work-related and general allergic respiratory 
symptoms (upper and lower) and asthma was computed. Key associations of interest involved 
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investigating the association between skin symptoms at baseline and subsequent development 
of allergic respiratory outcomes. The associations of interest were investigated among two 
groups of workers, viz. those who reported skin symptoms and those without skin symptoms 
at baseline using the Chi-square and Fisher’s exact tests where appropriate. These associations 
were further explored according to sensitization status. Unadjusted logistic regression was used 
to investigate the association between the incidence of respiratory outcomes and host factors 
(age, gender, atopy and smoking), environmental factors (job, personal protective equipment - 
PPE use) and skin symptoms at baseline. Multivariate logistic regression was used to further 
explore the association between skin symptoms at baseline and respiratory outcomes adjusting 
for atopy, gender and smoking. This multivariate regression analysis was further stratified by 
“glove use”, as a measure of effect modification. A two-tailed p-value of <0.05 considered to 
be statistically significant. 
 
RESULTS 
 
 
Study population 
 
 
The demographic characteristics of the 263 study subjects that participated in both baseline 
and the follow-up assessment are outlined in Table 1. Gender was well represented. Almost 
half of the study population was ever smokers (54% at baseline and 44% at follow-up) and 
current smokers at baseline had a 4-median pack-years smoking history. The most common 
job category among the participants was bakers and assistant bakers in both baseline (48%) 
and at follow-up (51%). The majority of workers (95%) reported using general personal 
protective equipment (aprons, gloves and masks) on a regular basis. However, only 32% 
reported using gloves and 2% used respirators. The majority of workers (90%) reported 
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washing hands six or more times per day and a few workers (4%) reported adverse reactions 
to grain products on ingestion. 
 
Atopy was presented in 32% individuals at baseline. Sensitization to at least one bakery 
related allergen was found in 26% and 33% of workers, at baseline and follow-up, 
respectively. Among those with sensitization to flour dust allergens, wheat and rye were the 
most common allergens and presented more individuals with elevated IgE levels whilst 
alpha-amylase were less so (Table 1). 
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Table 1. Demographics and allergic sensitization characteristics of supermarket bakery 
workers 
 
 
Subjects (N = 263) 
Baseline 
n (%) 
Follow up 
n (%) 
Sex (Female- Male) 132-131 132-131 
Age (median, IQR) 32 (26-38) 35 (24-41) 
Smoking status (ever smokers) 142 (54) 115 (44) 
History of current smoker’s pack years (median, IQR) 3.8 (2-8) * 
Duration of employment in current bakery (median, IQR) 5.5 (3-8) * 
Duration of employment in current job post (median, IQR) 3 (2-5) * 
Occupation (~) 
Counter hands 
Bakers and assistant bakers 
Confectioners 
Managers and supervisors 
Others 
 
54 (21) 
126 (48) 
31 (12) 
29 (11) 
23 (9) 
 
29 (13) 
111 (51) 
28 (13) 
51 (23) 
44 (17) 
General use of personal protective equipment on a regular basis 
Use of respirator only on a regular basis 
Use of gloves only on a regular basis 
249 (95) 
4 (2) 
85 (32) 
* 
* 
* 
Hand washing frequency 
Less than six times per day 
Six or more times per day 
 
25 (10) 
238 (900 
 
* 
* 
Self-reported adverse reactions to grain products 
Rye products 
Whole-wheat products 
White bread 
Breakfast cereals 
10 (4) 
6 (2) 
3 (1) 
0 
1 (0) 
* 
* 
* 
* 
* 
Baking activities at home 111 (42) * 
Eczema (childhood) 9 (3) * 
Atopy 85 (32) 85 (32) 
Sensitization to flour allergens (IgE>0.35 kU/L) (†) 
Wheat 
Rye 
Alpha-amylase 
To at least one flour dust allergen 
 
65 (25) 
61 (23) 
5 (1) 
68 (26) 
 
69 (32) 
62 (28) 
5 (2) 
72 (33) 
(*) – Data not available at follow-up; (~) n=219 for follow-up; (†) N=262 at baseline, N=219 for follow-up 
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Skin symptoms were present in 22% of participants, with 13% reporting two or more 
episodes of skin problems in the last 12 months (Table 2). The skin problems commonly 
affected the hands more than the entire body. While skin trauma (bruises, burns and injury) 
was highly prevalent (78%), work-related skin symptoms were reported in 11% of subjects. 
Stratifying according to sensitization status, certain skin symptoms affecting hands were 
more prevalent at baseline. These included having itchy/scratchy skin, hives or redness of the 
skin. The prevalence of work-related skin symptoms among sensitized workers (18%) was 
also two-fold higher that non-sensitized workers (9%). 
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Table 2. Prevalence of skin symptoms of supermarket bakery workers at baseline stratified according to sensitization status 
 
Skin symptoms 
Overall 
(N = 262) n (%) 
Presence of sensitization 
(N = 68) n (%) 
Absence of sensitization 
(N = 194) n (%) 
Chi-square 
p-value 
Presence of skin symptoms ever 58 (22) 15 (22) 43 (22) 0.986 
Two/more episodes of skin problems in the last 12 months 33 (13) 12 (18) 21 (11) 0.145 
Symptoms affecting the hands 
- Itchy/scratchy skin 
- Hives (”bommels”) 
- Dry, scaly skin 
- Redness of the skin 
- Blisters or weeping skin 
- Burning skin 
- Composite skin variable (**) 
Symptoms affecting the entire body 
- Itchy/scratchy skin 
- Hives (”bommels”) 
- Dry, scaly skin 
- Redness of the skin 
- Blisters or weeping skin 
- Burning skin 
 
20 (8) 
10 (4) 
15 (6) 
16 (6) 
3 (1) 
7 (2) 
23 (9) 
 
10 (15) 
7 (10) 
6 (9) 
8 (12) 
1 (1) 
4 (6) 
11 (16) 
 
10 (5) 
3 (2) 
9 (5) 
8 (42) 
2 (1) 
3 (2) 
12 (6) 
 
0.011† 
0.004*† 
0.227* 
0.036*† 
1.000* 
0.077* 
0.012† 
16 (6) 
6 (2) 
14 (5) 
13 (5) 
0 
4 (2) 
5 (7) 
3 (4) 
5 (7) 
3 (4) 
- 
1 (1) 
11 (6) 
3 (2) 
9 (5) 
10 (5) 
- 
3 (2) 
0.569* 
0.183* 
0.365* 
1.000* 
-    
1.000* 
Skin trauma (bruise, burn or injury) 205 (78) 55 (81) 149 (77) 0.486 
Work-related skin symptoms (~) 30 (11) 12 (18) 18 (9) 0.062 
Sensitization data available for N=262; (*) – Fisher’s exact test; (~)-unspecified body area, (**) – presence of Itchy/scratchy skin; or hives (”bommels”) or redness of skin; 
(†) p<0.05 
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From the general respiratory outcomes (Table 3), ocular-nasal symptoms were the most 
prevalent at both baseline (33%) and follow-up (36%). Lower respiratory symptoms (such as 
tight chest, wheeze, shortness of breath and cough) were lower at baseline (19%) than at 
follow-up (31%). The prevalence of asthma was however similar (8%) at both points of 
assessment. As expected, the incidence of work-related ocular-nasal symptoms (29%) was 
higher than lower respiratory symptoms (20%). The prevalence of allergic sensitization 
increased from 26% at baseline to 33% at follow-up with a cumulative incidence of 8% 
during this follow-up period. 
 
Table 3. General and work-related allergic or irritant respiratory outcomes and asthma 
at baseline and follow up among supermarket bakery workers 
 
Respiratory outcomes (N=263) 
Baseline 
Prevalence 
n (%) 
Follow up* 
Prevalence 
n (%) 
Follow up** 
Incidence 
N 
N (at 
risk) 
% 
General outcomes 
Ocular-nasal symptoms (~) 
Treatment for rhinitis 
Two or more lower respiratory symptoms (tight 
chest/wheeze/shortness of breath/cough) (~) 
Asthma 
Treatment for asthma 
 
87 (33) 
24 (9) 
 
 
50 (19) 
22 (8) 
11 (4) 
 
95 (36) 
13 (5) 
 
 
81 (31) 
21 (8) 
10 (4) 
 
34 
6 
 
 
47 
10 
6 
 
176 
239 
 
 
213 
241 
252 
 
19 
3 
 
 
22 
4 
2 
Work-related outcomes 
Ocular-nasal symptoms 
Lower respiratory symptoms (tight chest/wheeze) 
 
73 (28) 
37 (14) 
 
106 (40) 
64 (24) 
 
54 
45 
 
187 
222 
 
29 
20 
Sensitization to at least one flour dust allergen 68 (26) (†) 72 (33) (†) 16 194 8 
(*) subjects reporting current respiratory outcome at follow up (prevalence); (**) subjects reporting new onset 
respiratory outcome at follow up excluding those who reported at baseline (incidence); (~)-reported in the last 
12 months; (†) n= 262 at baseline, n= 219 at follow-up 
 
 
Further analysis demonstrated that the incidence of the various adverse respiratory outcomes 
(general and work-related symptoms) was not associated with the presence of skin symptoms 
at baseline (see Supplementary table 1), even after stratifying by sensitization status (see 
Supplementary table 2). 
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Host and environmental risk factors associated with respiratory outcomes 
 
 
Among the host factors, atopy was significantly associated with new-onset work-related 
lower respiratory symptoms, allergic airway inflammation and sensitization to at least one 
flour dust allergen (see Supplementary table 3). Childhood eczema was significantly 
associated with work-related rhinitis and lower respiratory symptoms. As expected, smoking 
was associated with a decreased risk of having high levels of FeNO. 
 
Among the environmental factors, being a manager or supervisor was significantly associated 
with an increased risk of developing ocular-nasal symptoms when compared to a counter 
hand (least exposed) (Supplementary table 4). Using general PPE on a regular basis was 
significantly associated with a decreased risk of developing ocular-nasal symptoms (RR=0.1, 
95% CI: 0.01-0.49), work-related rhinitis (RR=0.1, 95% CI: 0.02-0.51) and elevated FeNO 
levels (FeNO>25ppb RR=0.2, 95% CI: 0.06-0.53). 
 
 
Association between skin symptoms and the development of bakery respiratory outcomes 
 
 
In unadjusted models, workers with a history of an itchy or scratchy skin affecting the hands 
were at increased risk of developing ocular-nasal (RR=4.6, 95% CI: 1.09-19.44) and work- 
related lower respiratory symptoms (WRLRS) (RR=3.9, 95% CI: 1.33-11.39) 
(Supplementary table 5). Similarly, the risk of WRLRS was increased among workers 
reporting hives (RR=17.2, 95% CI: 1.87-157.7) and redness of the skin (RR=4.4, 95% CI: 
1.34-14.32), in both cases affecting the hands. Having clinically significant skin symptoms 
affecting the hands (itchy/scratchy skin, hives or redness), as defined by a composite skin 
variable, had an increased risk of developing WRLRS (RR=4.0, 95% CI: 1.50-11.6). A 
history of previous work-related skin symptoms was significantly associated with developing 
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ocular nasal symptoms (RR=3.9, 95% CI: 1.12-13.68), work-related respiratory symptoms 
(RR=3.6, 95% CI: 1.33-9.77) and allergic airway inflammation (RR=4.3, 95% CI: 1.83-
10.38) (Supplementary table 5). 
 
In multivariate logistic regression models (adjusting for gender, atopy and smoking status), 
having clinically significant skin symptoms affecting the hands was associated with an 
increased risk of developing ocular-nasal symptoms (RR=5.5, 95% CI: 1.30-24.20). A similar 
association was observed between having work-related skin symptoms and the development 
of ocular-nasal symptoms (RR=5.1, 95% CI: 1.31-19.81). For new onset WRLRS, an 
increased risk was associated with a past history of skin symptoms (RR=2.2, 95% CI: 1.03- 
4.83), having clinically significant skin symptoms affecting the hands (RR=4.8, 95% CI: 1.6- 
14.40), and having work-related skin symptoms (RR=4.1, 95% CI: 1.43-16.88). Furthermore, 
work-related skin symptoms increased the risk of developing having elevated FeNO levels of 
(FeNO>25ppb RR=2.9, 95% CI: 1.19-7.28) (Table 4). 
 
Further stratification based on glove use in adjusted logistic regression models revealed that 
workers with significant skin symptoms in the absence of glove use, were at higher risk of 
developing ocular-nasal symptoms (RR=5.8, 95% CI: 1.10-30.8) than their counterparts. For 
work-related skin symptoms, an increased risk of developing WRLRS (RR=5.3, 95% CI: 
1.54-18.4) and elevated FeNO levels (FeNO>25ppb RR=3.0, 95% CI: 1.07-8.45) was also 
observed (Table 5). 
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Table 4. Association between skin symptoms at baseline and development of new-onset bakery allergic or irritant respiratory symptoms 
and asthma in adjusted multivariate logistic regression models 
 
Adjusted risk ratio† (Confidence Interval) 
  
Presence of skin 
symptoms ever 
Two or more 
skin symptoms 
in the last 12 
months 
Itchy/scratchy 
skin affecting the 
hands 
Hives 
(”bommels”) 
affecting the 
hands 
Redness of the 
skin affecting the 
hands 
 
Composite skin 
variable 
 
Work-related 
skin symptoms 
Outcome 
New-onset self-reported 
ocular-nasal symptoms 
1.0 (0.43-2.67) 0.26 (0.04-1.71) 7.1 (1.51-32.92) ~ 6.5 (1.16-36.50) 5.5 (1.30-24.20) 5.1 (1.31-19.81) 
New-onset self-reported 
work-related rhinitis 
1.2 (0.55-2.81) 1.05 (0.23-4.80) 1.62 (0.36-7.27) ~ 3.16 (0.58-17.03) 2.2 (0.56-9.10) 0.7 (0.15-3.88) 
New-onset of 2/> lower 
respiratory symptoms 
1.6 (0.73-3.45) 0.5 (0.13-2.20) 1.3 (0.25-6.67) 5.2 (0.70-39.41) 2.0 (0.36-11.20) 2.8 (0.76-10.60) 2.8 (0.94-8.63) 
New-onset work-related 
lower respiratory 
symptoms 
 
2.2 (1.03-4.83) 
 
0.5 (0.11-2.21) 
 
4.4 (1.40-13.96) 
 
3.8 (0.99-14.61) 
 
4.7 (1.32-16.88) 
 
4.8 (1.60 -14.40) 
 
4.1 (1.43-11.85) 
FeNO >25ppb 
0.9 (0.41-1.93) 0.6 (0.14-3.03) 1.2 (0.36-4.09) 2.1 (0.47-9.61) 1.2 (0.31-4.93) 1.4 (0.45-4.14) 2.9 (1.19-7.28) 
FeNO 25-50ppb 1.1 (0.49- 2.73) 0.4 (0.06-2.17) 1.4 (0.39-5.44) 3.6 (0.84-15.40) 2.1 (0.54-8.37) 1.8 (0.54-5.80) 5.7 (2.26-14.60) 
FeNO >50ppb 
0.6 (0.15-2.10) ~ 0.7 (0.08-6.01) ~ ~ 0.6 (0.07-4.87) ~ 
Sensitization to at least 
one bakery related 
allergen 
 
1.2 (0.36-4.25) 
 
0.6 (0.07-5.15) 
 
~ 
 
~ 
 
~ 
 
~ 
 
0.9 (0.10-7.63) 
(†) Each risk ratio represents a separate model adjusted for atopy, gender and smoking status; (~) Risk ratio indeterminable. 
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Table 5. Association between composite skin variable and work-related skin symptoms at baseline and development of new-onset bakery 
allergic or irritant respiratory symptoms and asthma in adjusted multivariate logistic regression models 
 
Adjusted risk ratio† (Confidence Interval) 
 Composite skin variable Work related skin symptoms 
Overall With gloves Without gloves Overall With gloves Without gloves 
Outcome 
New-onset self-reported 
ocular-nasal symptoms 
5.5 (1.30-24.20) ~ 5.8 (1.10-30.8) 5.1 (1.31-19.81) 9.9 (0.40-243.9) 4.7 (0.85-26.26) 
New-onset self-reported 
work-related rhinitis 
2.2 (0.56-9.10) 5.5 (0.30-112.00) 1.8 (0.38-8.60) 0.7 (0.15-3.88) ~ 1.2 (0.20-7.31) 
New-onset of 2/> lower 
respiratory symptoms 
2.8 (0.76-10.60) 9.2 (0.65-131.79) 1.5 (0.30-8.51) 2.8 (0.94-8.63) 3.9 (0.45-33.85) 2.3 (0.60-8.54) 
New-onset work-related 
lower respiratory symptoms 
4.8 (1.60 -14.40) 7.4 (0.80-68.23) 4.1 (1.13-15.07) 4.1 (1.43-11.85) 2.1 (0.30-16.86) 5.3 (1.54-18.43) 
FeNO >25ppb 
1.4 (0.45-4.14) 1.9 (0.17-22.76) 1.3 (0.39-4.69) 2.9 (1.19-7.28) 3.7 (0.50-27.37) 3.0 (1.07-8.45) 
FeNO 25-50ppb 
1.8 (0.54-5.80) 1.5 (0.14-17.46) 1.9 (0.48-7.53) 5.7 (2.26-14.60) 4.2 (0.60-29.38) 7.6 (2.50-23.29) 
FeNO >50ppb 
0.6 (0.07-4.87) ~ 0.6 (0.07-5.46) ~ ~ ~ 
Sensitization to at least one 
bakery related allergen 
~ ~ ~ 0.9 (0.10-7.63) ~ 1.2 (0.12-11.67) 
(†) Each RR represents a separate model adjusted for atopy, gender and smoking status; (~) Risk ratio indeterminable. 
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DISCUSSION 
 
 
The results of this study add to the growing body of evidence that skin symptoms can be 
predictive of future development of adverse respiratory outcomes, including asthma-like 
symptoms and allergic airway inflammation in workers exposed to allergens. The findings 
are similar to other studies in bakers, workers employed in auto body repair, wood product 
manufacturing exposed to isocyanates as well as professional cleaners [6,16,30]. In the 
current study, bakers who reported clinical manifestations suggestive of urticarial or eczema 
(itchy/scratchy skin, hives and redness) of the hands were at significantly increased risk of 
developing upper airway symptoms and work-related lower respiratory symptoms, at the 
fourth year of follow-up. Furthermore, should the skin symptoms be work-related, other than 
being at increased risk of developing upper airway and work-related lower respiratory 
symptoms, bakery workers were at increased risk of developing allergic airway 
inflammation. 
 
The prevalence of skin symptoms in this current study (22%) was higher than that reported in 
bakers and confectioners (20% and 7%, respectively) [31], professional indoors cleaners 
(10%) and other building workers (6%) [30]. In some studies in the seafood-processing 
industry, the prevalence of skin symptoms was more than two-fold (43%) higher than the 
prevalence reported in the current study [32]. Additionally, Helaskoski et al. in a 
retrospective review of the patient information collected in a Finish occupational medicine 
clinic, reported a high prevalence of skin conditions due to high and low molecular weight 
agents (80% for contact urticaria and 20% for protein contact dermatitis), with flour, grains 
and animal feed being the most common causes implicated [33]. While 13% of subjects from 
the present study reported two or more episodes of skin symptoms in the last 12 months, 
Steiner et al. reported that 19% of workers in a Scottish bakery reported at least one skin 
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symptom in the previous 12 months [31]. Furthermore, professional indoors cleaners (19%) 
and other building workers (16%) reported similar figures for skin rash in the previous 12 
months [30]. While 11% of workers in the current study reported work-related skin 
symptoms, work-related itchy skin was reported in 17% of bakers and 9% auto body shop 
workers in a previous study [6]. Additionally, Arrandale et al. reported that 63% of workers 
exposed to a variety of agents (animal dander, cement, isocyanates, pesticides, wet work, 
dust, fumes, and paint) reported possible work-related skin rash [2]. This high prevalence is 
probably due to the study population being patients attending an occupational medicine 
clinic. Overall, this current study found that skin symptoms in bakery workers are more likely 
to be allergic in nature. A similar trend was observed in another study of bakers, in which 
workers sensitized to wheat were more likely to have itchy/dry skin or work-related itchy 
skin than their counterparts [6]. 
 
The current study in bakery workers found a considerably high prevalence and incidence of 
both general (36% and 19%, respectively) and work-related (40% and 29%, respectively). 
upper respiratory symptoms Studies in British bakeries also reported a high prevalence of 
general upper respiratory symptoms (38%), of which 19% was work-related [34]. Likewise, 
this current study found a high prevalence and incidence of general symptoms (for 31% and 
22%, respectively) and work-related (24% and 20%, respectively) lower respiratory 
symptoms). Comparable results were observed in the British bakeries reporting prevalence of 
35% for one or more general upper respiratory symptoms of which 13% were work-related 
[34]. Lower figures have been reported in wood product plant employees exposed to 
Methylene Diphenyl di-Isocyanate (MDI), with a prevalence of 20% for asthma-like 
symptoms and an incidence of 12% [16]. 
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Overall, the respiratory outcomes found in this study do not differ much in nature, in that 
almost similar proportions were found for allergic and irritant respiratory outcomes 
(Supplementary table 1). However, atopy and a history of childhood eczema were significant 
host factors associated with adverse respiratory outcomes. Atopy is regarded as a potent 
unmodifiable risk factor for sensitization to high molecular weight allergens in the workplace 
[35]. Furthermore, various other studies have demonstrated that the onset of atopic disease in 
childhood frequently occurs and manifests as an atopic dermatitis (AD) [37,38]. Laboratory 
studies have also demonstrated that percutaneous exposure to high-molecular weight 
allergens, such as ovalbumin, can lead to subsequent manifestations of the allergic respiratory 
response under conditions that trigger AD-like skin inflammation [35,39–41]. In this study, 
smoking status was associated with a decreased risk of having elevated FeNO levels 
(FeNO>25ppb RR=0.4, 95% CI: 0.24-0.82) as has been previously reported by Baatjes et al. 
[42] in the larger study of this group of workers. 
 
 
Among the environmental risk factors, being manager or supervisor was associated with an 
increased risk of developing upper respiratory symptoms when compared to counter hands 
(least exposed) [43]. Arakawa et al. demonstrated that the allergic response to 
Dermatophagoides farinae mite was dose-dependent in guinea pigs and asthma-like 
symptoms were triggered by increased doses of intradermal Tri-mellitic Anhydride (TMA) 
[23]. Also evident in this study was that general PPE use of any sort (aprons, mask, and 
gloves) on a regular basis was associated with a decreased risk of developing allergic airway 
inflammation. 
 
One of the key findings of this study was that the presence of skin symptoms at baseline was 
associated with future development of adverse respiratory outcomes. Helaskoski et al. also 
reported that 38% occupational rhinitis and 21% occupational asthma patients attending a 
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Finish occupational medicine clinic were concomitantly diagnosed with skin disorders [33]. 
Petsonk et al. investigated respiratory outcomes in workers exposed to low molecular weight 
agents (isocyanates) under strict conditions to prevent inhalational exposure [16]. He reported 
that 52% of workers with strong history of skin exposure (MDI stains) developed adverse 
respiratory outcomes [16]. Furthermore, in a recent review, 46% of occupational skin 
disorders occurred concomitantly with occupational airway disease caused by the same agent, 
suggesting a strong association between dermal exposure, sensitization and airway 
inflammation [33]. In the current study, a previous history of general skin symptoms or 
having clinically significant skin symptoms of urticaria or eczema affecting the hands, was 
strongly associated with the development of ocular-nasal and work-related lower respiratory 
symptoms. Furthermore, the presence of work-related skin symptoms at baseline was also 
strongly associated with an increased risk of developing allergic airway inflammation, ocular- 
nasal symptoms and work-related lower respiratory symptoms. Interestingly, the risk of 
developing work-related skin symptoms was modified by the use of dermal PPE (gloves). 
Bakers who reported clinically significant skin symptoms and did not use gloves had a higher 
risk of developing ocular-nasal symptoms (RR=5.8) and work-related lower respiratory 
symptoms (RR=4.1). Furthermore, those workers with work-related skin symptoms in the 
absence of  regular glove use, also had a higher risk of developing allergic airway 
inflammation (RR=3.0) and work-related lower respiratory symptoms (RR=5.3). 
 
The findings of  this study suggest that skin exposure may play an important role in the 
process of sensitization and the future development of respiratory symptoms, including 
asthma. This has been reported in some studies investigating the link between skin exposure 
to allergens and the future development of sensitization and respiratory disease [2,7,17]. 
However, the current study was unable to demonstrate an increased risk of developing 
sensitization to flour dust in this group. Nevertheless, the study did demonstrate that skin 
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symptoms can predict allergic airway inflammation, which may imply allergic sensitization 
in bakers [33]. Baatjies et al. have shown that sensitization to wheat is the strongest predictor 
of increased FeNO in this group of workers [42]. However, this does not exclude the 
possibility of an irritant cause for the upper and lower respiratory symptoms observed in the 
current study, since a sizeable proportion of bakers with respiratory symptoms may not 
demonstrate sensitization [44–47]. 
 
The major strength of this study is its cohort design and the use of sensitive markers to 
demonstrate airway inflammation present in asthma. The inability to demonstrate a positive 
association between skin symptoms and sensitization to the bakery allergens may be 
attributed to the lack of power due to the relatively small sample size. Furthermore, only 8% 
(16/194) of workers developed new sensitization to bakery allergens at follow-up, which may 
suggest a healthy worker effect. De Zotti et al. reported a cumulative incidence of 10% for 
sensitization in apprentice bakers after 30 months [48] Another limitation of this study was 
the fact that concurrent sensitization via skin and respiratory (inhalation) routes cannot be 
excluded, since the respiratory route was not strictly or minimally protected and that only 2% 
(4/249) of workers using general PPE reported regular mask use. Finally, the absence of more 
conventional measures for airway reversibility and asthma, such as spirometry (with 
bronchodilator challenge) or non-specific bronchial hyperresponsiveness at follow-up, also 
posed as limitations. This was partially compensated by the use of markers of allergic airway 
inflammation (FeNO) and respiratory symptoms to detect the presence of asthma. Since there 
may be other causes of a rise in FeNO, only levels >50ppb were considered as being 
suggestive of airway inflammation as is present in asthma. Future studies should include 
more objective measurements to improve the specificity of the respiratory outcomes of 
interest, as well as include exposures to both high and other low molecular weight agents not 
previously studied using prospective study designs. 
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In conclusion, the present study has demonstrated that skin symptoms in workers exposed to high 
molecular weight protein allergens, such as cereal flour dust, may predict the presence of general 
and work-related upper and lower respiratory symptoms and increased inflammatory marker levels 
suggestive of asthma. Medical surveillance programmes should also consider for inclusion the 
presence and distribution of skin symptoms when administering asthma symptom questionnaires. 
Furthermore, both skin and respiratory protection should be equally promoted so as to decrease the 
likelihood of sensitization and the development of upper and lower airway disease, including 
asthma, in high risk working populations. 
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SUPPLEMENTARY TABLES 
 
 
Supplementary table 1. New-onset general allergic or irritant respiratory symptoms and 
asthma among supermarket bakers stratified according to the presence of allergic skin 
symptoms at baseline 
Respiratory outcomes 
Presence of skin 
symptoms 
Absence of skin 
symptoms 
Chi-square 
p-value 
Overall (N = 262) 
New-onset self-reported ocular-nasal symptoms 
Newly prescribed treatment for rhinitis 
New-onset of two or more lower respiratory symptoms 
New-onset self-reported asthma 
Newly prescribed treatment for asthma 
FeNO >=25ppb 
- FeNO 25-50ppb 
- FeNO >50ppb 
n = 58 
7 (12) 
0 
12 (21) 
3 (5) 
1 (2) 
11 (19) 
8 (14) 
3 (5) 
n = 204 
27 (13) 
6 (3) 
35 (17) 
7 (3) 
5 (2) 
44 (21) 
26 (13) 
18 (9) 
 
0.816 
0.344* 
0.536 
0.465* 
1.000* 
0.668 
0.834 
0.583* 
With sensitization (N = 68) 
New-onset self-reported ocular-nasal symptoms 
Newly prescribed treatment for rhinitis 
New-onset of two or more lower respiratory symptoms 
New-onset self-reported asthma 
Newly prescribed treatment for asthma 
FeNO >=25ppb 
- FeNO 25-50ppb 
- FeNO >50ppb 
n = 15 
2 (13) 
0 
3 (20) 
2 (13) 
0 
6 (40) 
4 (27) 
2 (13) 
n = 53 
7 (13) 
4 (8) 
10 (19) 
7 (13) 
5 (9) 
24 (45) 
11 (21) 
13 (25) 
 
1.000* 
0.569* 
1.000* 
1.000* 
0.579* 
0.716 
0.726* 
0.492* 
Without sensitization (N= 194) 
New-onset self-reported ocular-nasal symptoms 
Newly prescribed treatment for rhinitis 
New-onset of two or more lower respiratory symptoms 
New-onset self-reported asthma 
Newly prescribed treatment for asthma 
FeNO >=25ppb 
- FeNO 25-50ppb 
- FeNO >50ppb 
n = 43 
5 (12) 
0 
9 (21) 
1 (2) 
1 (2) 
5 (12) 
4 (9) 
1 (2) 
n = 151 
20 (13) 
2 (1) 
25 (17) 
0 
0 
20 (13) 
15 (10) 
5 (3) 
 
0.780 
1.000* 
0.506 
0.222* 
0.222* 
0.780 
1.000* 
1.000* 
(*) – Fisher’s exact test 
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Supplementary table 2. Presence of new-onset work-related allergic or irritant respiratory symptoms and asthma among bakers 
stratified according to the presence of skin symptoms at baseline 
 
 
 
Work-related respiratory outcomes 
Presence of skin 
symptoms 
n (%) 
Absence of skin 
symptoms 
n (%) 
 
Chi-square 
p-value 
Overall (N = 258) (†) 
- New-onset self-reported work-related rhinitis (sneezy/itchy/runny nose or 
red/itchy/watery eyes) 
- New-onset work-related lower respiratory (tight chest or wheeze) 
n=58 
11 (19) 
 
14 (24) 
n=200 
43 (22) 
 
31 (16) 
 
0.676 
 
0.127 
With sensitization (N = 67) 
- New-onset self-reported work-related rhinitis (sneezy/itchy/runny nose or 
red/itchy/watery eyes) 
- New-onset work-related lower respiratory (tight chest or wheeze) 
n=15 
2 (13) 
 
5 (33) 
n=52 
12 (23) 
 
13 (25) 
 
0.431 
 
0.495 
Without sensitization (N = 191) 
- New-onset self-reported work-related rhinitis (sneezy/itchy/runny nose or 
red/itchy/watery eyes) 
- New-onset work-related lower respiratory (tight chest or wheeze) 
n=43 
9 (21) 
 
9 (21) 
n=148 
31 (21) 
 
18 (12) 
 
0.954 
 
0.132 
(†) N=258 due to missing data on work related symptoms for 4 participants at follow-up 
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Supplementary table 3. Host risk factors associated with the development of new-onset bakery allergic or irritant respiratory symptoms 
and asthma 
 
Risk ratio (Confidence Interval) 
 
Age 
Gender 
(male) 
Smoking 
 
Atopy 
History of 
childhood eczema 
Hand trauma 
Hand washing 
frequency ( >6 
times per day) 
Outcome 
New-onset self-reported 
ocular-nasal symptoms 
1.0 (0.94-1.03) 0.9 (0.43-1.94) 0.9 (0.41-1.84) 2.0 (0.91-4.58) 1.0 (0.11-9.66) 1.2 (0.49-3.04) 1.8 (0.38-8.09) 
New-onset self-reported 
work-related rhinitis 
1.0 (0.96-1.04) 1.2 (0.62-2.19) 1.1 (0.56-2.00) 1.8 (0.90-3.51) 10.6 (1.15-96.78) 1.1 (0.54-2.35) 0.6 (0.22-1.48) 
New-onset 2/> lower 
respiratory symptoms 
1.0 (0.95-1.03) 0.6 (0.34-1.25) 0.8 (0.41-1.51) 1.7 (0.87-3.40) 7.6 (1.35-43.04) 0.8 (0.37-1.76) 1.3 (0.42-4.07) 
New-onset of work- 
related lower 
respiratory symptoms 
 
1.0 (0.95-1.03) 
 
0.6 (0.31-1.17) 
 
1.3 (0.67-2.50) 
 
2.6 (1.35-5.19) 
 
4.1 (0.81-21.26) 
 
1.0 (0.45-2.17) 
 
0.7 (0.25-2.16) 
FeNO >25ppb 
1.0 (0.94-1.02) 1.4 (0.77-2.54) 0.4 (0.24-0.82) 2.7 (1.49-5.06) 1.9 (0.47-8.03) 1.4 (0.63-2.88) 0.6 (0.26-1.64) 
FeNO 25-50ppb 
1.0 (0.95-1.04) 1.2 (0.56-2.37) 0.6 (0.27-1.15) 1.6 (0.74-3.26) 0.8 (0.10-6.91) 0.9 (0.39-2.13) 0.8 (0.24-2.36) 
FeNO >50ppb 
1.0 (0.90-1.02) 1.7 (0.68-4.27) 0.4 (0.15-1.02) 4.8 (1.87-12.44) 3.5 (0.69-18.21) 2.9 (0.65-12.66) 0.6 (0.16-2.20) 
Sensitization to at least 
one flour dust allergen 
0.9 (0.90-1.03) 0.9 (0.34.2.67) 0.6 (0.23-1.80) 4.4 (1.55-12.66) ~ 1.3 (0.36-4.92) ~ 
(~) Risk ratio indeterminable. 
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Supplementary table 4. Environmental risk factors associated with the development of new-onset bakery allergic or irritant respiratory 
symptoms and asthma 
Risk ratio (Confidence Interval) 
 Job type 
(bakers, confectioners 
and M&S) (†) 
Employment 
duration 
General PPE use on a 
regular basis 
Respiratory PPE use 
on a regular basis 
(mask) 
Dermal PPE use on a 
regular basis (gloves) 
Outcome 
New-onset self- 1.8 (0.57-5.88)     
reported ocular- 0.8 (0.13-4.63) 1.0 (0.91-1.06) 0.1 (0.01-0.49) ~ 0.5 (0.19-1.14) 
nasal symptoms 4.2 (1.04-16.73)     
New-onset self- 1.1 (0.45-2.52)     
reported work- 0.6 (0.17-2.23) 1.0 (0.89-1.03) 0.1 (0.02-0.51) ~ 0.7 (0.38-1.48) 
related rhinitis 1.2 (0.35-3.81)     
New-onset 2/> lower 1.06 (0.45-2.47)     
respiratory 1.00 (0.29-3.17) 1.0 (0.93-1.06) 0.8 (0.16-4.32) ~ 0.8 (0.41-1.68) 
symptoms 2.25 (0.77-6.51)     
New-onset work- 
related lower 
respiratory 
symptoms 
0.5 (0.20-1.04) 
0.4 (0.09-1.37) 
1.6 (0.57-4.58) 
 
1.0 (0.93-1.06) 
 
0.50 (0.15-1.65) 
 
~ 
 
1.5 (0.77-3.00) 
 1.0 (0.43-2.24)     
FeNO >25ppb 1.1 (0.34-3.25) 0.9 (0.88-1.01) 0.2 (0.06-0.53) 1.25 (0.13-12.41) 1.0 (0.54-1.93) 
 1.1 (0.37-3.56)     
 0.6 (0.23-1.58)     
FeNO 25-50ppb 0.6 (0.15-2.52) 0.9 (0.84-1.00) 0.1 (0.04-0.37) 2.29 (0.23-22.60) 1.3 (0.64-2.85) 
 0.9 (0.25-3.36)     
FeNO >50ppb 
2.5 (0.53-11.62) 
2.8 (0.44-17.67) 
 
0.9 (0.89-1.07) 
 
1.1 (0.14-9.13) 
 
~ 
 
0.6 (0.22-1.79) 
 1.9 (0.26-14.44)     
Sensitization to at 0.9 (0.30-3.42)     
least one flour dust 2.5 (0.56-11.09) 0.9 (0.89-1.10) ~ ~ 1.1 (0.37-3.08) 
allergen ~     
M&S = Managers and supervisors; (†) Counter hands as a reference category; (~) Risk ratio indeterminable. 
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Supplementary table 5. Association between skin symptoms at baseline and development of new-onset bakery allergic or irritant 
respiratory symptoms and asthma in unadjusted multivariate logistic regression models 
 
 
Risk ratio† (Confidence Interval) 
  
Presence of skin 
symptoms ever 
Two or more 
skin symptoms 
in the last 12 
months 
Itchy/scratchy 
skin affecting the 
hands 
Hives 
(” bommels”) 
affecting the 
hands 
Redness of the 
skin affecting the 
hands 
 
Composite skin 
variable 
 
Work-related 
skin symptoms 
Outcome 
New-onset self-reported 
ocular-nasal symptoms 
1.1 (0.42-2.67) 1.9 (0.61-5.71) 4.6 (1.09-19.44) ~ 4.5 (0.86-23.28) 3.6 (0.92-14.41) 3.9 (1.12-13.68) 
New-onset self-reported 
work-related rhinitis 
1.2 (0.55-2.72) 1.1 (0.37-3.43) 1.5 (0.35-6.53) ~ 2.5 (0.50-13.05) 2.0 (0.53-8.00) 0.7 (0.14-3.44) 
New-onset of 2/> lower 
respiratory symptoms 
1.5 (0.70-3.20) 1.9 (0.66-5.31) 1.0 (0.20-5.03) 3.6 (0.50-26.60) 1.4 (0.27-7.62) 2.1 (0.60-7.55) 2.6 (0.86-7.58) 
New-onset work- 
related lower 
respiratory symptoms 
 
2.0 (0.98-4.28) 
 
2.3 (0.92-5.91) 
 
3.9 (1.33-11.39) 
 
17.2 (1.87-157.7) 
 
4.4 (1.34-14.32) 
 
4.0 (1.50-11.6) 
 
3.6 (1.33-9.77) 
FeNO >25ppb 
0.9 (0.41-1.79) 1.0 (0.42-2.49) 0.9 (0.30-2.94) 1.7 (0.41-6.63) 0.9 (0.24-3.15) 1.0 (0.37-3.00) 2.1 (0.91-4.77) 
FeNO 25-50ppb 
1.1 (0.47-2.58) 1.6 (0.61-4.22) 1.2 (0.33-4.36) 3.1 (0.75-12.49) 1.6 (0.43-5.96) 1.5 (0.50-4.62) 4.3 (1.83-10.38) 
FeNO >50ppb 
0.6 (0.16-2.00) 0.3 (0.04-2.53) 0.6 (0.07-4.61) ~ ~ 0.5 (0.06- 3.90) ~ 
Sensitization to at least 
one bakery related 
allergen 
 
1.1 (0.36-3.89) 
 
0.5 (0.06-4.20) 
 
~ 
 
~ 
 
~ 
 
~ 
 
1.7 (0.07-5.07) 
(†) Each RR represents a separate unadjusted regression model; (~) Risk ratio indeterminable. 
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APPENDIX 1: ARTICLE - SKIN EXPOSURE, SYMPTOMS AND ASTHMA IN 
OCCUPATIONAL SETTINGS – IS THERE A LINK? 
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UCT OCCUPATIONAL ALLERGY AND ASTHMA STUDY AMONG 
BAKERY WORKERS IN THE WESTERN CAPE PROVINCE 
OF SOUTH AFRICA-2003 
ENGLISH QUESTIONNAIRE 
APPENDIX 4: ENGLISH QUESTIONNAIRE- BASELINE 
 
 
 
 
Survey Number    
Card 1  
 
1-3 
 
A. IDENTIFICATION DATA 
 
 
1. Surname    
 
 
2. First name/s    
 
 
3. Address    
 
 
 
 
4. Work number    
      
4-9 
         
        10- 
5. Date of birth: Day  Month  Year         15 
         
6. Gender: Male (1) 
      
16 
 
Female (2) 
       
7. Home Language: English (1) 
      
17 
 
Afrikaans (2) 
       
Xhosa (3) 
Other (4) 
       
8. Interviewer's initials         18 
 
 
9. Date of interview: 
       
       19- 
 Day  Month  Year        24 
        
       25- 
10. Bakery:         26 
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11.Are you a casual or permanent worker? 
 
 
Casual (1) 
  
27 
 
Permanent (2) 
 
 
 
 
B.HEALTH PROBLEMS 
 
Wheeze and tightness in the chest 
 
1. Have you ever had wheezing or whistling in your 
chest in the past? 
 
Yes (1) 
  
28 
 
No (2) 
 
 
If YES, go on to Question 1.1 
 If NO, skip to Question 2 
 
 
1.1 If yes, when was the first time you had these 
symptoms.  
 
Date: 
 
Month  Year    
     29- 
32 
 
 
1.2 Have you had wheezing or whistling in your chest at 
 
any time in the last 12 months? 
 
Yes (1) 
  
33 
 
No (2) 
 
 
If YES, go on to Question 1.2.1 
 If NO, skip to Question 2 
 
 
1.2.1 Have you been short of breath when the wheezing 
noise was present? 
 
Yes (1) 
  
34 
 
No (2) 
 
 
1.2.2 Have you had this wheezing or whistling when you 
did not have a cold or flu? 
 
Yes (1) 
  
35 
 
No (2) 
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2. Have you been woken up with a feeling of tightness 
   
in your chest at any time in the last 12 months?    
Yes (1) 
  
36 
No (2) 
   
 
 
 
 
 
Shortness of breath 
   
 
3. Have you had an attack of shortness of breath that 
   
came on during the daytime when you were at rest at    
any time in the last 12 months?    
Yes (1) 
  
37 
No (2) 
   
 
4. Have you had an attack of shortness of breath that 
   
came on following running or exercise at any time in the    
last 12 months?    
Yes (1) 
  
38 
No (2) 
   
 
5. Have you been woken by an attack of shortness of 
   
breath at any time in the last 12 months?    
Yes (1) 
  
39 
No (2) 
   
 
Cough and phlegm from the chest 
   
 
6. Have you been woken by an attack of coughing at any 
   
time in the last 12 months?    
Yes (1) 
  
40 
No (2) 
   
 
7. Do you usually cough first thing in the morning? 
   
Yes (1) 
  
41 
No (2) 
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8. Do you usually cough during the rest of the day, or
at night? 
Yes (1) 42 
No (2) 
If YES, go on to Question 8.1 
If NO, skip to Question 9 
8.1 Do you cough like this on most days/nights for as 
much as three or more months in each of the last 
two years? 
Yes (1) 43 
No (2) 
9. Do you usually bring up any phlegm from your chest
first thing in the morning? 
Yes (1) 44 
No (2) 
10. Do you usually bring up any phlegm from your chest
during the day, or at night? 
Yes (1) 45 
No (2) 
If YES, go on to Question 10.1 
If NO, skip to Question 11 
10.1 Do you bring up phlegm like this on most days/ 
nights for as much as three or more months in each of 
the last two years? 
Yes (1) 46 
No (2) 
Breathing 
11. Do you ever have trouble with your breathing? 47 
Yes (1) 
No (2)
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If YES, go on to Question 11.1 
  
If NO, skip to Question 12  
 
 
11.1 Do you have this trouble: 
  
48 
 
Give all options at once 
 
Insert a cross (X) next to one answer only 
 
 
a) continuously so that your breathing is never 
 
quite right?  
b) repeatedly, but it goes away completely 
 
between the times when it troubles you?  
c) only rarely? 
 
 
 
12. Are you disabled from walking by a condition other 
 
than heart or lung disease? 
   
49 
Yes (1) 
  
No (2)  
If YES, state the condition    
and go on to Question 13  
If NO, go to Question 12.1  
 
 
12.1 Are you troubled by shortness of breath when 
 
hurrying on level ground or walking up a slight hill?  
Yes (1) 
   
50 
No (2) 
  
If YES, go on to Question 12.1.1 
 
If NO, skip to Question 13  
 
 
12.1.1 Do you get short of breath walking with other 
 
people of your own age on level ground?  
Yes (1) 
   
51 
No (2) 
  
 
12.1.1.1 Do you have to stop for breath when walking at 
 
your own pace on level ground?  
Yes (1) 
   
52 
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No (2) 
  
 
Asthma 
 
 
13. Have you ever had asthma? 
 
Yes (1) 
   
53 
No (2) 
  
If YES, go on to Question 13.1 
 
If NO, skip to Question 13.8  
 
 
13.1 If yes, was this confirmed by a doctor? 
 
Yes (1) 
   
54 
No (2) 
  
 
13.2 How old were you when you were told you have 
 
asthma? 
   
55 
   
Give all options at once 
 
Insert a cross (X) next to one answer only  
 
 
a) Only before you were 17 years old    
 
b) Only at the age of 17 years or older     
c) Both     
The following references to "attack" of asthma refers to episodes of 
 
wheezing, shortness of breath, chest tightness or cough attributed 
 
to asthma  
 
 
13.3.1 How old were you when you had your first attack 
 
of asthma?  
 
  years old 
    56- 
57 
 
 
13.3.2 How old were you when you had your most 
  
recent attack of asthma?  
 
  years old 
    58- 
59 
 
 
13.4.1-6 Which months of the year do you usually have 
  
attacks of asthma?  
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13.4.1 January/February 
   
Yes (1) 
  
60 
No (2) 
   
 
13.4.2 March/April 
   
Yes (1) 
  
61 
No (2) 
   
 
13.4.3 May/June 
   
Yes (1) 
  
62 
No (2) 
   
 
13.4.4 July/August 
   
Yes (1) 
  
63 
No (2) 
   
 
13.4.5 September/October 
   
Yes (1) 
  
64 
No (2) 
   
 
13.4.6 November/December 
   
Yes (1) 
  
65 
No (2) 
   
 
 
 
 
13.5 Have you had an attack of asthma in the last 
   
12 months?    
Yes (1) 
  
66 
No (2) 
   
If YES, go on to Question 13.5.1 
   
If NO, skip to Question 13.6    
 
 
13.5.1 How often have you had an attack of asthma in 
   
the last 12 months? 
  
 
 
67 
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Give all options at once 
Insert a cross (X) next to one answer only 
 
a) Every day 
b) More than 2 times a week    
c) More than 1 time per month    
d) 3 to 12 times in the whole year    
e) 1 to 2 times in the whole year    
 
13.6 Are your chest symptoms caused by, or made 
worse by any of the following: 
 
Answer all questions 
 
 
13.6.1 Contact with animals/pets 
Yes (1) 68 
No (2) 
13.6.2 Grass or flowers 
Yes (1) 69 
No (2) 
13.6.3 Heavy exercise 
Yes (1) 70 
No (2) 
13.6.4 Breathing cold air 
Yes (1) 71 
No (2) 
13.6.5 Dusts or sprays at work 
Yes (1) 72 
No (2) 
13.6.6 Tobacco smoke 
Yes (1) 73 
No (2) 
13.6.7 Change in the weather 
Yes (1) 74 
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75 
76 
77- 
80 
Card 2 
1 
2 
No (2) 
13.7 Do your chest symptoms seem better or worse 
when you are away from work (for example, on 
weekends, off-shift and vacations)? 
Give all options at once 
Insert a cross (X) next to one answer only 
a) Stay the same
b) Get better
c) Get worse
13.8 Does being at work ever make your tight chest 
or wheezy? 
Yes (1) 
No (2) 
If YES, go on to Question 13.8.1 
If NO, skip to Question 13.9 
13.8.1 When did you first notice having problems with 
chest tightness or wheeze at work? 
Date: Month Year 
13.8.2 Is there anything that you work with that causes 
you to have these chest symptoms? 
Yes (1) 
No (2) 
If YES, go on to Question 13.8.3 (specify wheat, rye &/or premix) 
or any other substance 
If NO, skip to Question 13.9 
13.8.3 What do you think is causing these symptoms? 
13.9 Have you ever had to change or leave your work 
area, either temporarily or permanently, in this bakery 
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or any other bakery because of any chest symptoms? 
Yes (1) 3 
No (2) 
If YES, go on to Question 13.9.1 
If NO, skip to Question 13.10 
13.9.1 What type of job were you doing when this 
happened? 
4-5
13.9.2 Was this a job in this bakery? 
Yes (1) 6 
No (2) 
If YES, go on to Question 13.9.2.1 
If NO, skip to Question 13.10 
13.9.2.1 What area/section did you move to? 
7-8
13.9.2.2 What job did you do there? 
9- 
10 
13.9.2.3 Did your symptoms improve when you changed 
jobs? 
Yes (1) 11 
No (2) 
13.10 Have you ever worked in a job or jobs that 
exposed you to vapours, gas, dust or fumes? 
Yes (1) 12 
No (2) 
If YES, go on to Question 13.10.1. 
List the jobs beginning with the most recent 
If NO, skip to Question 13.11 
13.10.1 What was or is this job? 
13- 
14 
(if current job write 'current job') 
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13.10.2 Before that?    
    
15- 
16 
     
 
13.10.3 Before that?    
   17- 
18 
 
 
13.11 Has there ever been an instance when you inhaled 
    
a large amount of vapour, gas, dust or fumes in any of     
these jobs that resulted in you developing a tight chest,     
wheeze or cough?     
Yes (1) 
   
19 
No (2) 
    
If YES, go on to Question 13.11.1. 
    
If NO, skip to Question 13.12     
     
 
13.11.1 What was or is this job?    
   20- 
21 
(if current job write 'current job') 
    
 
13.12 Are you using any medicines, including inhalers/ 
    
pumps, nebulizers, syrups or tablets, for asthma or     
breathing problems?     
Yes (1) 
   
22 
No (2) 
    
If YES, go on to Question 13.12.1, showing examples of each 
    
If NO, skip to question 13.13     
 
 
13.12.1 Which medicines? 
    
    
23 
    
24 
    
25 
 
 
13.12.2 Do you take these medicines every day even 
    
when you do not have any trouble breathing?     
Yes (1) 
   
26 
No (2) 
    
 
13.13 Have you ever been treated for any of the 
    
following:     
Answer all questions 
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13.13.1 Repeated chest infections as a child 
     
Yes (1) 
    
27 
No (2) 
     
UNK (3)      
 
 
13.13.2 Tuberculosis (TB) 
     
Yes (1) 
    
28 
No (2) 
     
UNK (3)      
 
13.13.3 Chronic bronchitis 
     
Yes (1) 
    
29 
No (2) 
     
UNK (3)      
 
Nose and eye symptoms 
     
 
14. Have you ever had any nose or eye problems or 
     
allergies such as hay fever?      
Yes (1) 
    
30 
No (2) 
     
If YES, go on to Question 14.1 Answer all questions 
     
If NO, skip to Question 14.4      
 
 
14.1 How old were you when you first noticed these 
     
symptoms?      
 
  years old 
    31- 
32 
 
 
14.2 During the past 12 months have you had two or 
     
more episodes of:      
14.2.1 sneezy, itchy or runny nose when you did not      
have a cold or flu?      
Yes (1) 
    
33 
No (2) 
     
 
14.2.2 red, itchy or watery eyes 
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Yes (1) 34 
No (2) 
14.2.3 Do you usually have the nose or eye symptoms 
at any particular time of the year? 
Yes (1) 35 
No (2) 
14.2.3.1 If YES, which is the worst season? 36 
Give all options at once 
Insert a cross (X) next to one answer only 
 
 
 
a) Winter    
b) Spring    
c) Summer    
d) Autumn    
 
If YES to any of the above in question 14.2, go on to Question 14.3 
If NO, skip to Question 14.4 
 
14.3 Do your nose or eye symptoms seem better or 
worse when you are away from work (for example, on 
weekends, off-shift and vacations)? 37 
Give all options at once 
Insert a cross (X) next to one answer only 
 
a) Stay the same    
b) Get better    
c) Get worse    
 
14.4 Does being at work ever cause you to have sneezy/ 
itchy/runny nose or red/itchy/watery eyes? 
Yes (1) 38 
No (2) 
If YES to any one of the above, go on to Question 14.4.1 
If NO, skip to Question 14.5 
14.4.1 Since when have you been having these 
symptoms at work? 
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Date: Month  Year    
     39- 
42 
 
14.4.2 Is there anything that you work with that causes 
      
you to have these symptoms?       
Yes (1) 
     
43 
No (2) 
      
If YES, go on to Question 14.4.3 (specify wheat, rye &/or premix) 
      
or any other substance       
If NO, skip to Question 14.5       
 
14.4.3 What do you think is causing these symptoms? 
      
     
 
44 
 
 
 
 
 
 
 
 
14.5 Are you using any medicines, including nose 
      
sprays, drops, tablets or injections, for any nose or eye       
symptoms at present?       
Yes (1) 
     
45 
No (2) 
      
If YES, go on to Question 14.5.1 
      
If NO, go on to Question 14.6       
       
Present a chart with different samples of allergy medicines 
      
(N.B. a worker might show you his/her medicines).       
       
14.5.1 Which medicines? 
     
46 
       
     
 
47 
 
14.6 Did you have hay fever (itchy or watery eyes/nose) 
      
as a child?       
Yes (1) 
     
48 
No (2) 
      
Skin symptoms 
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15. Have you ever had any kind of skin problem either
at home or at work? 
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49 
50- 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
Yes 
No 
(1) 
(2) 
If YES, go on to Question 15.1 
If NO, skip to Question 15.4 
15.1 How old were you when you first noticed this skin 
problem? 
years old 
15.2 During the past 12 months have you had any skin 
problems that occurred 2 or more times? 
Yes (1) 
No (2) 
If Yes, which of the following problems did you have? 
Go through each option in the table below and circle the 
appropriate response. 
Forearms Whole 
Hands Body 
15.2.1 
itchy or Yes/No Yes/No 
scratchy skin 
15.2.2 
hives Yes/No Yes/No 
(“bommels”) 
15.2.3 
dry, scaly Yes/No Yes/No 
skin 
15.2.4 
redness of Yes/No Yes/No 
the skin 
15.2.5 
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blisters or Yes/No Yes/No 61 
weeping skin 
  
62 
   
 
15.2.6    
burning skin Yes/No Yes/No 63 
   64 
15.2.7    
started within 
   
an hour of Yes/No Yes/No 65 
contact with 
  
66 
a substance    
or food item    
   
Card 3 
15.2.8 
  
1 
Other? Yes/No Yes/No 2 
Specify: 
   
    
If YES, to any of the above go on to Question 15.3 
If NO, skip to Question 15.4 
 
15.3 Do your skin problems seem better or worse when 
you are away from work (for example, on weekends, 
off-shift and vacations)? 
  
3 
    
Give all options at once 
Insert a cross (X) next to one answer only 
  
 
 
 
 
a) Stay the same 
 
 
 
 
 
   
 b) Get better     
 c) Get worse     
 
15.4 Does being at work ever cause you to have any skin 
problems? 
  
4 
  
Yes (1) 
 
  No (2)  
If YES, go on to Question 15.4.1 
If NO, skip to Question 15.4.4 
 
15.4.1 Since when have you been having these skin 
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5-8 
 
 
 
 
9 
 
 
 
 
 
 
 
 
 
10 
 
 
 
 
 
11 
 
 
 
 
12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13 
    
 
problems at work? 
 
Date: Month  Year    
 
15.4.2 Is there anything that you work with that makes 
these skin problems worse? 
Yes (1) 
No (2) 
 
If YES, go on to Question 15.4.3 (specify wheat, rye &/or premix) 
or any other substance 
If NO, skip to Question 15.4.4 
 
15.4.3 What do you think is causing these skin 
problems? 
 
 
15.4.4 Have you ever bruised, burnt or injured your 
fingers or hands while working in the bakery? 
Yes (1) 
No (2) 
 
 
15.5 How many times do you wash your hands in the 
course of a day? 
Give all options at once 
Insert a cross (X) next to one answer only 
 
0    
1 time    
2-3 times    
4-5 times    
6 or more    
 
 
 
 
15.6 Are you using any medicines, including any creams 
or ointments, for your skin problems at present? 
Yes (1) 
No (2) 
If YES, go on to Question 15.6.1 
If NO, skip to next question 15.7 
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15.6.1 Which medicines? 
  
14 
    15 
    
 
15.7 Did you have eczema as a child? 
  
Yes (1) 
  
16 
  
No (2) 
 
 
Other allergic conditions 
 
16. Are you allergic to insect stings or bites? 
  
Yes (1) 
  
17 
  
No (2) 
 
  
If YES, go on to Question 16.1 
  If NO, skip to Question 17 
 
16.1.1-3 What kind of reactions do you have? 
 
16.1.1 Breathing difficulty, feeling faint, fever? 
  
Yes (1) 
  
18 
  
No (2) 
 
 
16.1.2 Redness, itching or swelling at the sting site 
  
Yes (1) 
  
19 
  
No (2) 
 
16.1.3 Other:    
  
20 
 
17. Have you ever had any difficulty with your breathing 
 
after taking medications or injections that you did not 
have before?   
  
Yes (1) 
  
21 
  
No (2) 
 
 
 
 
 
 
 
 
22 
  
If YES, go on to Question 17.1 
  If NO, skip to 18.1 
 
17.1 Which medici 
 
nes? 
 
 
 
  
   
 
18.1-6 When you are near animals (such as cats, dogs 
or horses), near feathers (including pillows, quilts or 
duvets), near grass and flowers, or in a dusty part of the 
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house, do you ever 
   
 
18.1 Start to cough? 
   
Yes (1) 
  
23 
No (2) 
   
 
18.2 Start to wheeze? 
   
Yes (1) 
  
24 
No (2) 
   
 
18.3 Get a tight chest? 
   
Yes (1) 
  
25 
No (2) 
   
 
18.4 Start to feel short of breath? 
   
Yes (1) 
  
26 
No (2) 
   
 
18.5 Get a runny/stuffy nose or sneeze? 
   
Yes (1) 
  
27 
No (2) 
   
 
18.6 Get itchy or watery eyes? 
   
Yes (1) 
  
28 
No (2) 
   
 
18.7 Get itchy skin/rash? 
   
Yes (1) 
  
29 
No (2) 
   
 
19. Have you ever had an illness or trouble caused by 
   
eating a particular type of food/fruit?    
Yes (1) 
  
30 
No (2) 
   
If YES, go on to Question 19.1 
   
If NO, skip to 20    
 
19.1 What type of food/fruit was this? 
   
  
 
31 
 
19.1.1-6 Did this illness or trouble include: 
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19.1.1 Itchy skin or rash 
Yes (1) 32 
No (2) 
19.1.2 Diarhoea or vomiting 
Yes (1) 33 
No (2) 
19.1.3 Runny or stuffy nose 
Yes (1) 34 
No (2) 
19.1.4 Severe headaches 
Yes (1) 35 
No (2) 
19.1.5 Breathlessness/tight chest/wheeze 
Yes (1) 36 
No (2) 
19.1.6 Other: 37 
19.2 Was the food canned or preserved? 
Yes (1) 38 
No (2) 
UNK (3) 
19.3 Do you experience these problems when you drink 
fizzy drinks also? 
Yes (1) 39 
No (2) 
C. FAMILY HISTORY
1. Do/did any members of your family (blood relatives)
ever have any kind of allergies? 40 
Do not include relatives by marriage 
If family history is completely unknown (subject is adopted, etc.), 
mark UNK and do not complete table. Move to next section 
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41 
42 
43 
44 
45 
46 
47- 
48 
Yes (1) 
No (2) 
UNK (3) 
If YES, complete table below. Insert a cross (X) in the appropriate 
block for each option 
Type of NO ONE YES, present in the family Do Not 
Allergy in family Parent Brother/ Child Know 
Sister 
1.1 Hay fever 1 2 3 4 5 
1.2 Eczema 1 2 3 4 5 
1.3 Asthma 1 2 3 4 5 
1.4 Flour 1 2 3 4 5 
related Allergy 
1.5 Other 1 2 3 4 5 
allergy 
Specify: 
D. SMOKING HISTORY
1. Have you ever smoked tobacco (cigarettes or pipe) for
as long as a year? 
‘YES’ means at least 20 packs of cigarettes or 360 grams of tobacco 
in a lifetime or at least one cigarette per day for one year 
Yes (1) 
No (2) 
If YES, go on to Question 1.1 
If NO, skip to Question 2 
1.1 How old were you when you started smoking? 
years old 
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49 
 
 
 
 
 
 
 
 
 
 
 
 
50- 
51 
 
 
52- 
54 
 
 
 
 
55 
 
 
 
 
 
 
 
 
 
56- 
57 
 
 
 
 
 
58- 
59 
 
 
 
 
 
60- 
61 
 
 
62- 
64 
 
 
1.2 Do you now smoke? 
 
‘YES’ means smoking tobacco in the last month or more 
Yes (1) 
No (2) 
If YES, go on to Question 1.2.1 
If NO, skip to Question 1.3.1 
 
 
 
 
 
1.2.1-2. How much do you now smoke on average? 
 
 
1.2.1 Number of cigarettes per day 
 
 
1.2.2 Pipe tobacco in grams/week 
 
1.3. Have you stopped smoking completely? 
Yes (1) 
No (2) 
If YES, go on to Question 1.3.1 
If NO, skip to Question 1.4 
 
1.3.1. How old were you when you stopped smoking 
completely? 
  years old 
 
1.3.1.1 How many years in total did you smoke 
cigarettes? (Do not include the years you stopped before 
you started again) 
  years 
 
1.3.2.1-2 On average of the entire time you smoked, 
how much did you smoke? 
 
1.3.2.1 Number of cigarettes per day 
 
 
1.3.2.2 Pipe tobacco in grams/week 
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65 
 
 
 
 
 
 
 
 
 
 
66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Card 4 
1 
 
 
2 
 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
 
 
 
 
8 
1.4 Do you or did you inhale the smoke? 
Yes (1) 
No (2) 
 
 
2. Have you been regularly exposed to tobacco smoke 
from other people smoking cigarettes or pipe in the last 
12 months? 
 
‘Regularly’ means on most days or nights 
Yes (1) 
No (2) 
 
E. DIETARY HISTORY/DOMESTIC ACTIVITIES 
 
1. How often have you eaten the following grain 
products in the last 12 months? 
 
Go through each wheat product option and insert a cross (X) in the 
block for each option 
Type of wheat Daily 1 to 3 1 to 3 Never 
product  times a times per  
  week month  
     
1.1 White 1 2 3 4 
bread/Rolls 
    
1.2 Brown 1 2 3 4 
bread/Rolls     
1.3 Whole 
    
wheat bread/ 1 2 3 4 
rolls 
    
1.4 Rye bread/ 1 2 3 4 
rolls 
    
2. Pastries 1 2 3 4 
     
3. Cereals 1 2 3 4 
     
4. Biscuits 1 2 3 4 
containing     
wheat     
     
5.Pasta 1 2 3 4 
containing     
wheat     
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6. Other 1 2 3 4 
  
9 
Specify:      
     
     
     
 
2.Have you changed your diet or avoided certain grain 
  
(eg. wheat/rye/soya) products because they do not   
agree with you when you eat them?    
  
Yes (1) 
    
10 
  
No (2) 
   
 
If YES, go on to Question 2.1 
 
 If NO, skip to Question 3   
   
2.1 What grain products have you avoided? 
    
11 
   12 
   
 
3. Do you bake at home? 
    
  
Yes (1) 
    
13 
  
No (2) 
   
 
If YES, go on to Question 3.1 
 
 If NO, go to Question 4   
   
3.1 How often do you do baking at home? 
    
14 
 a) once a month    
 
b) 2-3 times a month 
 
   
 c) 2-3 times per week     
 d) once a week     
 e) everyday      
 
3.2 What do you bake? 
    
 
a) bread/rolls 
 
   
  
15 
 
b) cakes/biscuits 
 
   
 
16 
 
c) tarts/pastries 
 
   
 
17 
 
d) Other: 
  
   
 
18 
 
 
Specify:   
   
 
4. Does any one else bake at home? 
   
  
Yes (1) 
    
19 
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No (2) 
       
 
F. HEALTH AND SAFETY EDUCATION AND TRAINING 
 
1. What are the hazards associated with flour dust? 
       
20 
       
21 
 
 
 
2. Have you had any health and safety training on how 
to protect yourself when working with flour dust? 
 
Yes (1) 
      
22 
 
No (2) 
       
 
G. WORK HISTORY IN THE BAKERY INDUSTRY 
 
1. How long have you been working at this bakery? 
  
  years 
      23- 
26 
  months 
 
Present job 
        
 
2. How long have you been working in your current 
job?         
  
  years 
      27- 
30 
  months 
 
3. In which area/section are you currently working? 
      31- 
32 
 
 
 
3.1 What is your job in this area/section? 
 
Job Title 
 
   
     33- 
34 
        
get a short description of the job 
 
 
 
 
3.2 What products do you produce: 
 
a) doughs Yes (1) 
     
35 
  
No (2) 
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b) pastry Yes (1) 36 
No (2) 
c) croissants Yes (1) 37 
No (2) 
d) bread,rolls Yes (1) 38 
No (2) 
e) cakes/tarts Yes (1) 39 
No (2) 
f) biscuits Yes (1) 40 
No (2) 
g) confectionary Yes (1) 41 
No (2) 
h) other Yes (1) 42 
No (2) 
Specify: 
3.3 What ingredients do you work with? 
a) Flour (wheat, rye) 43 
Yes (1) 
No (2) 
b) Baking additives (premix) 44 
Yes (1) 
No (2) 
c) Icing sugar 45 
Yes (1) 
No (2) 
d) Nuts (peanuts, hazelnuts) 46 
Yes (1) 
No (2) 
e) Seeds (sesame, lupine) 47 
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Yes (1) 
No (2) 
f) Other Yes (1) 48 
No (2) 
Specify: 
3.4 Do you ever do other jobs during your shift on a 
regular basis (almost every day)? 
Yes (1) 49 
No (2) 
If Yes, which jobs? 50 
51 
3.5 How much dust would you say your current job 
produces: 52 
Give all options at once 
Insert a cross (X) next to one answer only 
a) None
b) A little
c) An average amount
d) A lot
3.5.1 What aspect of your work would you say is 
very dusty? 
a) Tipping/Dispensing 53 
Yes (1) 
No (2) 
N/A (3) 
b) Weighing 54 
Yes (1) 
No (2) 
N/A (3) 
c) Sifting 55 
Yes (1) 
No (2) 
N/A (3)
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d) Mixing 
 
 
56 
Yes (1)    
No (2)    
N/A (3)    
e) brushing table 
  
57 
  
Yes (1) 
   
  No (2)    
  N/A (3)    
f) dough handling 
  
58 
  
Yes (1) 
   
  No (2)    
  N/A (3)    
g) other 
  
59 
  
Yes (1) 
   
  No (2)    
  N/A (3)    
 
Specify:   
   
 
3.5.1.1 What type of cleaning activities in your daily 
   
work are very dusty.    
3.5.1.1.1 Cleaning work table surfaces?    
Yes (1) 
    
60 
No (2) 
     
N/A (3)      
 
3.5.1.1.2 Sweeping floors? 
   
Yes (1) 
    
61 
No (2) 
     
N/A (3)      
 
3.5.1.1.3 Cleaning equipment (mixers, cutters) 
   
Yes (1) 
    
62 
No (2) 
     
N/A (3)      
3.5.2 How far do you work from the source of the dust? 
  
 
63 
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Give all options at once 
Insert a cross (X) next to one answer only 
 
 
 
a) Right next to the source 
 
 
 
   
    
b) About 1-2 metres away        
c) More than 3 metres away        
d) Does not apply        
 
3.6 Do you use any personal protective equipment on a 
regular basis (almost every day) while doing your job? 
 
Yes (1) 
    
64 
 
No (2) 
     
If NO, skip to Question 4 
If YES, continue with Question 3.6.1 
 
3.6.1 Which of the following personal protective 
equipment do you use on a regular basis (almost every 
day)?       
3.6.1.1 Goggles: Yes (1) 
    
65 
 
No (2) 
     
3.6.1.2 Gloves: Yes (1) 
    
66 
 
No (2) 
     
3.6.1.3 Mask: Yes (1) 
    
67 
 
No (2) 
     
3.6.1.4 Aprons: Yes (1) 
    
68 
 
No (2) 
     
3.6.1.5 Other:    
   
69 
      
If NO to all of the previous questions, skip to Question 4 
If YES to any one of the above questions, continue with 
Question 3.6.2.1       
       
 
3.6.2.1 Goggles 
 
   
 
years 
   70- 
71 
       
 
3.6.2.2 Gloves: 
 
   
 
years 
   72- 
73 
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    74- 
3.6.2.3 Mask:    years   75 
      
     76- 
3.6.2.4 Aprons:    years   77 
      
     78- 
3.6.2.5 Other:    years   79 
 
 
 
 
 
Previous jobs in present bakery Card 5 
 
4. Before doing this job at this bakery, did you do a 
different job here? 
Yes (1) 1 
No (2) 
If NO, skip to question 5 
If YES, continue with question 4.1 
4.1 What other jobs did you do here? 
Start with the first job and work forward, getting a one-line 
description of each job. If casual worker, denote each period of 
employment as a separate job. For continuous years of seasonal 
work consider as one job (provided no broken years service) 
Job 1 
4.1.1 Area/section   2-3 
4.1.2 Job Title   4-5 
get a short description of the job 
4.1.3 Permanent/casual: 6 
 
 
4.1.4. How long did you work in this job? 
7- 
  years 10 
  months 
4.1.5 What products did you produce: 
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a) doughs Yes (1) 
 
 
11 
 No (2)    
b) pastry Yes (1) 
  
12 
 
No (2) 
   
c) croissants Yes (1) 
  
13 
 
No (2) 
   
d) bread,rolls Yes (1) 
  
14 
 
No (2) 
   
e) cakes/tarts Yes (1) 
  
15 
 
No (2) 
   
f) biscuits Yes (1) 
  
16 
 
No (2) 
   
g) confectionary Yes (1) 
  
17 
 
No (2) 
   
h) other Yes (1) 
  
18 
 
No (2) 
   
Specify:       
 
4.1.6 What ingredients did you work with? 
    
a) Flour (wheat, rye) 
   
19 
 
Yes (1) 
   
 No (2)    
b) Baking additives (premix) 
   
20 
 
Yes (1) 
   
 No (2)    
c) Icing sugar 
   
21 
 
Yes (1) 
   
 No (2)    
d) Nuts (peanuts, hazelnuts) 
   
22 
 
Yes (1) 
   
 No (2)    
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e) Seeds (sesame, lupine) 23 
Yes (1) 
No (2) 
f) Other 24 
Yes (1) 
No (2) 
Specify: 
4.1. 7 How much dust would you say that this job 
produced: 25 
Give all options at once 
Insert a cross (X) next to one answer only 
a) None
b) A little
c) An average amount
d) A lot
4.1.8 What aspect of your work would you say was 
very dusty? 
a) Tipping/Dispensing 26 
Yes (1) 
No (2) 
N/A (3) 
b) Weighing 27 
Yes (1) 
No (2) 
N/A (3) 
c) Sifting 28 
Yes (1) 
No (2) 
N/A (3) 
d) mixing 29 
Yes (1) 
No (2) 
N/A (3)
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e) brushing table
Yes (1) 
No (2) 
N/A (3) 
f) dough handling
Yes (1) 
No (2) 
N/A (3) 
g) other
Yes (1) 
No (2) 
N/A (3) 
Specify: 
4.1.8.1. What type of cleaning activities in your daily 
work were very dusty. 
4.1.8.1.1. Cleaning work table surfaces? 
Yes (1) 
No (2) 
N/A (3) 
4.1.8.1.2 Sweeping floors? 
Yes (1) 
No (2) 
N/A (3) 
4.1.8.1.3 Cleaning equipment (mixers, cutters) 
30 
31 
32 
33 
34 
Yes (1) 35 
No (2) 
N/A (3) 
4.1.9 How far did you work from the source of the dust? 36 
Give all options at once 
Insert a cross (X) next to one answer only 
a) Right next to the source
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b) About 1-2 metres away    
    
c) More than 3 metres away        
d) Does not apply        
 
4.1.10 Did you use any personal protective equipment 
on a regular basis (almost every day) while doing your 
job?       
 
Yes (1) 
    
37 
 
No (2) 
     
If NO, skip to Question 4.2.1 
If YES, continue with Question 4.1.10.1 
 
4.1.10.1Which of the following personal protective 
equipment did you use on a regular basis (almost every 
day)?       
4.1.10.1.1 Goggles: Yes (1) 
    
38 
 
No (2) 
     
4.1.10.2 Gloves: Yes (1) 
    
39 
 
No (2) 
     
4.1.10.3 Mask: Yes (1) 
    
40 
 
No (2) 
     
4.1.10.4 Aprons: Yes (1) 
    
41 
 
No (2) 
     
4.1.10.5 Other:    
   
42 
      
If NO to all of the previous questions, skip to Question 4.2.1 
If YES to any one of the above questions, continue with 
Question 4.1.11.1       
       
 
4.1.11.1 Goggles 
 
   
 
years 
   43- 
44 
       
 
4.1.11.2 Gloves: 
 
   
 
years 
   45- 
46 
       
 
4.1.11.3 Mask: 
 
   
 
years 
   47- 
48 
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49- 
50 
 
51- 
52 
 
 
 
 
53- 
54 
 
55- 
56 
 
 
 
 
 
 
57 
 
 
 
58- 
61 
 
 
 
 
62 
 
 
 
63 
 
 
 
64 
 
 
 
65 
 
 
 
66 
 
 
 
67 
 
 
 
68 
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h) other 
 
 
Yes 
 
 
(1) 
  
 
 
 
69 
 No (2)    
 
Specify:   
    
 
4.2.6 What ingredients did you work with? 
    
a) Flour (wheat, rye) 
   
70 
 
Yes (1) 
   
 No (2)    
b) Baking additives (premix) 
   
71 
 
Yes (1) 
   
 No (2)    
c) Icing sugar 
   
72 
 
Yes (1) 
   
 No (2)    
d) Nuts (peanuts, hazelnuts) 
   
73 
 
Yes (1) 
   
 No (2)    
e) Seeds (sesame, lupine) 
   
74 
 
Yes (1) 
   
 No (2)    
f) Other 
   
75 
 
Yes (1) 
   
 No (2)    
 
Specify:   
    
 
4.2.7 How much dust would you say that this job 
  
Card 6 
  
produced: 
   
1 
     
Give all options at once 
    
Insert a cross (X) next to one answer only 
 
a) None 
    
b) A little 
    
c) An average amount    
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d) A lot 
 
 
 
4.2.8 What aspect of your work would you say was 
 
very dusty?  
a) Tipping/Dispensing 2 
Yes (1) 
 
No (2)  
N/A (3)  
b) Weighing 3 
Yes (1) 
 
No (2)  
N/A (3)  
c) Sifting 4 
Yes (1) 
 
No (2)  
N/A (3)  
d) mixing 5 
Yes (1) 
 
No (2)  
N/A (3)  
e) brushing table 6 
Yes (1) 
 
No (2)  
N/A (3)  
f) dough handling 7 
Yes (1) 
 
No (2)  
N/A (3)  
g) other 8 
Yes (1) 
 
No (2)  
N/A (3)  
 
Specify:   
 
 
4.2.8.1. What type of cleaning activities in your daily 
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work were very dusty. 
4.2.8.1.1.Cleaning work table surfaces? 
Yes (1) 9 
No (2) 
N/A (3) 
4.2.8.1.2 Sweeping floors? 
Yes (1) 10 
No (2) 
N/A (3) 
4.2.8.1.3 Cleaning equipment (mixers, cutters) 
Yes (1) 11 
No (2) 
N/A (3) 
4.2.9 How far did you work from the source of the dust? 12 
Give all options at once 
Insert a cross (X) next to one answer only 
a) Right next to the source
b) About 1-2 metres away
c) More than 3 metres away
d) Does not apply
4.2.10 Did you use any personal protective equipment on 
a regular basis (almost every day) while doing your job? 
Yes (1) 13 
No (2) 
If NO, skip to Question 4.3.1 or 5 if no other jobs 
If YES, continue with Question 4.2.10.1 
4.2.10.1Which of the following personal protective 
equipment did you use on a regular basis (almost every 
day)? 
4.2.10.1.1 Goggles: Yes (1) 14 
No (2)
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4.2.10.2 Gloves: Yes (1) 15 
No (2) 
4.2.10.3 Mask: Yes (1) 16 
No (2) 
4.2.10.4 Aprons: Yes (1) 17 
No (2) 
4.2.10.5 Other: 18 
19- 
4.2.11.1 Goggles years 20 
21- 
4.2.11.2 Gloves: years 22 
23- 
4.2.11.3 Mask: years 24 
25- 
4.2.11.4 Apron: years 26 
27- 
4.2.11.5 Other: years 28 
Job 3 
29- 
4.3.1 Area/section 
4.3.2 Job Title 
30 
31- 
32 
4.3.3 Permanent/casual: 33 
4.3.4. How long did you work in this job? 
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  years 
      34- 
37 
  months 
 
4.3.5 What products did you produce: 
       
a) doughs Yes (1) 
     
38 
 
No (2) 
      
b) pastry Yes (1) 
     
39 
 
No (2) 
      
c) croissants Yes (1) 
     
40 
 
No (2) 
      
d) bread,rolls Yes (1) 
     
41 
 
No (2) 
      
e) cakes/tarts Yes (1) 
     
42 
 
No (2) 
      
f) biscuits Yes (1) 
     
43 
 
No (2) 
      
g) confectionary Yes (1) 
     
44 
 
No (2) 
      
h) other Yes (1) 
     
45 
 
No (2) 
      
 
Specify:   
       
 
4.3.6 What ingredients did you work with? 
       
a) Flour (wheat, rye) 
      
46 
 
Yes (1) 
      
 No (2)       
b) Baking additives (premix) 
      
47 
 
Yes (1) 
      
 No (2)       
c) Icing sugar 
      
48 
 
Yes (1) 
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No (2) 
 
 
d) Nuts (peanuts, hazelnuts) 
 
49 
Yes (1) 
No (2) 
 
 
e) Seeds (sesame, lupine) 
 
50 
Yes (1) 
No (2) 
 
 
f) Other 
 
51 
Yes (1) 
No (2) 
 
Specify:   
 
4.3.7 How much dust would you say that this job 
produced: 52 
Give all options at once 
Insert a cross (X) next to one answer only 
 
 
a) None 
 
b) A little 
 
c) An average amount    
d) A lot    
 
4.3.8 What aspect of your work would you say was 
very dusty? 
a) Tipping/Dispensing 53 
Yes (1) 
No (2) 
N/A (3) 
 
 
b) Weighing 
 
54 
Yes (1) 
No (2) 
N/A (3) 
 
 
c) Sifting 
 
55 
Yes (1) 
No (2) 
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N/A (3) 
   
d) mixing 
  
56 
  
Yes (1) 
   
  No (2)    
  N/A (3)    
e) brushing table 
  
57 
  
Yes (1) 
   
  No (2)    
  N/A (3)    
f) dough handling 
  
58 
  
Yes (1) 
   
  No (2)    
  N/A (3)    
g) other 
  
59 
  
Yes (1) 
   
  No (2)    
  N/A (3)    
 
Specify:   
   
 
4.3.8.1. What type of cleaning activities in your daily 
   
work were very dusty.    
4.3.8.1.1.Cleaning work table surfaces?    
Yes (1) 
    
60 
No (2) 
     
N/A (3)      
 
4.3.8.1.2 Sweeping floors? 
   
Yes (1) 
    
61 
No (2) 
     
N/A (3)      
 
4.3.8.1.3 Cleaning equipment (mixers, cutters) 
   
Yes (1) 
    
62 
No (2) 
     
N/A (3)      
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63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
64 
 
 
 
 
 
 
 
 
 
 
 
 
65 
 
 
 
66 
 
 
 
67 
 
 
 
 
68 
 
 
 
69 
 
 
4.3.9 How far did you work from the source of the dust? 
Give all options at once 
Insert a cross (X) next to one answer only 
 
a) Right next to the source    
b) About 1-2 metres away    
c) More than 3 metres away    
d) Does not apply    
 
4.3.10 Did you use any personal protective equipment on 
a regular basis (almost every day) while doing your job? 
Yes (1) 
No (2) 
If NO, skip to Question 4.4.1 or 5 
If YES, continue with Question 4.3.10.1 
 
4.3.10.1 Which of the following personal protective 
equipment did you use on a regular basis (almost every 
day)? 
 
4.3.10.1.1 Goggles: Yes (1) 
No (2) 
 
4.3.10.2 Gloves: Yes (1) 
No (2) 
 
4.3.10.3 Mask: Yes (1) 
No (2) 
 
 
 
4.3.10.4 Aprons: Yes (1) 
No (2) 
 
4.3.10.5 Other:    
If NO to all of the previous questions, skip to Question 4.4.1 or 5 
If YES to any one of the above questions, continue with 
Question 4.3.11.1 
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4.3.11.1 Goggles years 
70- 
71 
4.3.11.2 Gloves: years 
72- 
73 
4.3.11.3 Mask: years 
74- 
75 
4.3.11.4 Apron: years 
76- 
77 
4.3.11.5 Other: years 
78- 
79 
Job 4 
4.4.1 Area/section 
Card 7 
1-2
4.4.2 Job Title 3-4
get a short description of the job 
4.4.3 Permanent/casual: 5 
4.4.4. How long did you work in this job? 
years 
months 
6-9
4.4.5 What products did you produce: 
a) doughs Yes (1) 10 
No (2) 
b) pastry Yes (1) 11 
No (2) 
c) croissants Yes (1) 12 
No (2) 
d) bread,rolls Yes (1) 13 
No (2) 
e) cakes/tarts Yes (1) 14 
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No (2) 
f) biscuits Yes (1) 15 
No (2) 
g) confectionary Yes (1) 16 
No (2) 
h) other Yes (1) 17 
No (2) 
Specify: 
4.4.6 What ingredients did you work with? 
a) Flour (wheat, rye) 18 
Yes (1) 
No (2) 
b) Baking additives (premix) 19 
Yes (1) 
No (2) 
c) Icing sugar 20 
Yes (1) 
No (2) 
d) Nuts (peanuts, hazelnuts) 21 
Yes (1) 
No (2) 
e) Seeds (sesame, lupine) 22 
Yes (1) 
No (2) 
f) Other 23 
Yes (1) 
No (2) 
Specify: 
4.4.7 How much dust would you say that this job 
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produced: 24 
Give all options at once 
Insert a cross (X) next to one answer only 
 
a) None 
 
b) A little 
 
c) An average amount    
d) A lot    
 
4.4.8 What aspect of your work would you say was 
very dusty? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) Tipping/Dispensing 
    
25 
 
Yes (1) 
   
 No (2)    
 N/A (3)    
b) Weighing 
    
26 
 
Yes (1) 
   
 No (2)    
 N/A (3)    
c) Sifting 
    
27 
 
Yes (1) 
   
 No (2)    
 N/A (3)    
d) mixing 
    
28 
 
Yes (1) 
   
 No (2)    
 N/A (3)    
e) brushing table 
    
29 
 
Yes (1) 
   
 No (2)    
 N/A (3)    
f) dough handling 
    
30 
 
Yes (1) 
   
 No (2)    
 N/A (3)    
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g) other 
Yes (1) 
No (2) 
N/A (3) 
 
 
Specify:   
 
 
4.4.8.1. What type of cleaning activities in your daily 
work were very dusty. 
4.4.8.1.1. Cleaning work table surfaces? 
Yes (1) 
No (2) 
N/A (3) 
 
 
4.4.8.1.2 Sweeping floors? 
Yes (1) 
No (2) 
N/A (3) 
 
 
4.4.8.1.3 Cleaning equipment (mixers, cutters) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31 
 
 
 
 
 
 
 
 
 
 
 
 
 
32 
 
 
 
 
 
 
33 
Yes (1) 
   
34 
No (2) 
    
N/A (3)     
4.4.9 How far did you work from the source of the dust? 
   
35 
     
Give all options at once 
    
Insert a cross (X) next to one answer only     
 
a) Right next to the source 
b) About 1-2 metres away 
 
   
   
   
c) More than 3 metres away 
d) Does not apply 
   
   
   
 
4.4.10 Did you use any personal protective equipment 
on a regular basis (almost every day) while doing your 
job? 
Yes        (1) 
No         (2) 
 
If NO, skip to Question 5 
If YES, continue with Question 4.4.10.1 
  
 
 
 
 
 
 
 
 
 
 
 
 
36 
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4.4.10.1Which of the following personal protective 
equipment did you use on a regular basis (almost every 
day)?       
4.4.10.1.1 Goggles: Yes (1) 
    
37 
 
No (2) 
     
4.4.10.2 Gloves: Yes (1) 
    
38 
 
No (2) 
     
4.4.10.3 Mask: Yes (1) 
    
39 
 
No (2) 
     
4.4.10.4 Aprons: Yes (1) 
    
40 
 
No (2) 
     
4.4.10.5 Other:    
   
41 
      
If NO to all of the previous questions, skip to Question 5 
If YES to any one of the above questions, continue with 
Question 4.4.11.1       
       
 
4.4.11.1 Goggles 
 
   
 
years 
   42- 
43 
       
 
4.4.11.2 Gloves: 
 
   
 
years 
   44- 
45 
       
 
4.4.11.3 Mask: 
 
   
 
years 
   46- 
47 
       
 
4.4.11.4 Apron: 
 
   
 
years 
   48- 
49 
       
 
4.4.11.5 Other: 
 
   
 
years 
 
  
50- 
51 
 
 
 
Previous work in other bakeries 
     
 
5. Have you worked in any other bakeries in the past 
     
two years?       
 
Yes (1) 
    
52 
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No (2)  
 
 
 
 
 
 
 
53 
 
If NO, skip to question 6 
   
 If YES, continue with question 5.1   
 
5.1 Why did you change jobs? 
    
   
   
 
5.2 What is the total amount of time you have worked in 
  
the bakery industry before you started working in    
this bakery?      
   
Years  Months    
       54- 
57 
 
Previous work experience 
          
 
6. Name all the previous workplaces that you have 
         
worked in, when not working in this bakery or before          
coming to work in this bakery:           
Start with the first job and work forward (including all 
         
other bakeries and jobs done)           
       
Name of What did Job Title Date Date Total       
Company company (what did start stop (yrs)       
 make? you do?) (Year) (Year)        
            
            
            
            
           58 
            
           59 
       
THANK YOU FOR ANSWERING THE QUESTIONNAIRE 
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APPENDIX 5: ENGLISH QUESTIONNAIRE- FOLLOW UP 
UCT OCCUPATIONAL ALLERGY AND ASTHMA STUDY AMONG 
BAKERY WORKERS IN THE WESTERN CAPE PROVINCE 
OF SOUTH AFRICA-2006 
ENGLISH QUESTIONNAIRE 
Survey Number 
A. IDENTIFICATION DATA
1. Surname
2. First name/s
3. Work number
4. Date of birth: Day Month Year 
5. Gender: Male (1) 
Female (2) 
8. Interviewer's initials
9. Date of interview:
Day Month Year 
10. Bakery:
11. Did you change your job since the last interview?
Yes (1) 
No (2) 
Not applicable (3) 
11.1 If Yes or NA, what is your new job? 
12. Which shift have you been working today?
04:00-12:00 (1) 
07:00-16:00 (2) 
08:00-17:00 (3) 
09:00-18:00 (4) 
12:00-21:00 (5) 
B.HEALTH PROBLEMS
Recent chest infections
1. Have you had the flu or sinusitis in the past 3 weeks?
Yes (1) 
No (2)
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2. Have you had any of the following symptoms in the past 12
months (at night, with exercise, exposure to cold air,
work exposures)?
2.1 chest tightness Yes (1) 
No (2) 
2.2 shortness of breath Yes (1) 
No (2) 
2.3 wheezing or whistling in your chest Yes (1) 
No (2) 
2.4 dry cough Yes (1) 
No (2) 
2.5 Asthma Yes (1) 
No (2) 
3. Are you being treated for Tuberculosis (TB)?
Yes (1) 
No (2) 
3.1 If yes, for how long? months weeks 
If YES, to question no 3, indicate to person that the tests will not be 
done today. Schedule another appointment in three months time 
since the start of TB medication. 
Nose and eye symptoms 
4. Have you ever had any nose or eye problems due to allergies
and/or hay fever?
Yes (1) 
No (2) 
C. SMOKING HISTORY
1. Do you smoke?
Yes (1) 
No (2) 
1.1 If yes, have you smoked tobacco (cigarettes or pipe) for as long 
as a year? 
Yes (1) 
No (2) 
1.2 If yes, how many cigarettes per day do you smoke or 
did you smoke? 
1.3 Have you smoked (cigarettes/tobacco) in the last hour? 
Yes (1) 
No (2)
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D. ALCOHOL CONSUMPTION 
1. Do you drink alcohol? 
 
 
Yes (1) 
No (2) 
 
1.1 If yes, when have you last consumed alcohol?  
1-2 hours ago (1) 
1 day ago (2) 
1 week ago (3) 
 
1.2 How much alcohol did you consume? 
 
 
E. MEDICATION USAGE (show booklet) 
1. Are you taking any medicine/s from a doctor or clinic at the 
moment for asthma, and or hayfever? 
Yes (1) 
No (2) 
 
1.1 If yes, what are you taking and when last did you take them? 
Names No. of hours since last dose 
 
 
 
 
F. GREEN VEGETABLE CONSUMPTION 
1. How often do you eat the following vegetable products? 
 
 
 
 
1.1 Green 
salad 
1.2 Spinach & 
other green 
leafy vegetables 
Type of 
product 
Daily 
 
 
1 
 
1 
1 to 3 
times a 
week 
2 
 
2 
1 to 3 
times per 
month 
3 
 
3 
Never 
 
 
4 
 
4 
 
2. When did you last consume green salad and/or spinach/other 
green leafy vegetables? 
1-2 hours ago (1) 
1 day ago (2) 
1 a week ago (3) 
 
 
 
 
G. PHYSICAL ACTIVITY 
1. Do you exercise? 
 
 
Yes (1) 
No (2) 
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2. When was the last time you exercised?  
1-2 hours ago (1) 
1 day ago (2) 
1 week ago (3) 
H. SPIROMETRY/LUNG FUNCTION TEST 
 
1. Have you ever had a spirometry/lung function test?  
Yes (1)  
No (2)  
2. If yes, when last did you blow into a lung function machine? 
 
1-2 hours ago (1) 
1 day ago (2) 
1 week ago (3) 
> a week ago (4) 
I. RECENT FOOD INTAKE 
 
1. Did you have anything to eat or drink in the last hour?  
Yes (1)  
No (2)  
If YES to above question, reschedule test for at least 1 hour later  
the same day or another date.  
 
J. WORK-RELATED SYMPTOMS 
 
1. Does being at work ever make your tight chest  
or wheezy?  
Yes (1)  
No (2)  
2. Does being at work ever cause you to have sneezy/ 
 
itchy/runny nose or red/itchy/watery eyes?  
Yes (1)  
No (2)  
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APPENDIX 6: SKIN PRICK TEST PRETEST DATA COLLECTION SHEET 
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APPENDIX 7: SKIN PRICK TEST DATA COLLECTION SHEET 
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APPENDIX 8: LUNG FUNCTION TEST PRETEST DATA COLLECTION SHEET 
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APPENDIX 9: LUNG FUNCTION TEST DATA COLLECTION SHEET 
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APPENDIX 10: EXHALED NITRIC OXIDE PRE-TEST DATA COLLECTION 
SHEET 
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APPENDIX 11: EXHALED NITRIC OXIDE DATA COLLECTION SHEET 
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APPENDIX 12: GUIDELINES FOR AUTHORS FOR CHOSEN JOURNAL 
(OCCUPATIONAL AND ENVIRONMENTAL MEDICINE) 
Authors 
Occupational and Environmental Medicine is an international peer reviewed journal covering 
current developments in occupational and environmental health worldwide. Occupational and 
Environmental Medicine publishes high-quality research relating to the full range of chemical, 
physical, ergonomic, biological and psychosocial hazards in the workplace and to 
environmental contaminants and their health effects. The journal welcomes research aimed at 
improving the evidence-based policy and practice of occupational and environmental research; 
including the development and application of novel biological and statistical techniques in 
addition to evaluation of interventions in controlling occupational and environmental risks. 
Editorial policy 
Occupational and Environmental Medicine adheres to the highest standards concerning its 
editorial policies on publication ethics, scientific misconduct, consent and peer review criteria. 
To view all BMJ Journal policies please refer to the BMJ Author Hub policies page. 
Articles are published under an exclusive licence (or non-exclusive licence for UK Crown and 
US Federal Government employees) and authors retain copyright. Articles can also be 
published under a Creative Commons licence to facilitate reuse of the content; please refer to 
the Occupational and Environmental Medicine Copyright Author Licence Statement. 
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Presentation of statistical data 
 
 
We strongly encourage authors to observe the following guidelines: 
 
 
• Only essential tables and graphs should be included. Large tables should be kept to a 
minimum. 
• Epidemiological measures of association (e.g. ratios or differences of rates, risks, 
odds, or prevalences) are preferred for contrasts of disease occurrence. 
• Confidence intervals should be reported for measures of association. 
 
• P-values may be reported if necessary for tests such as trend tests or non-parametric 
tests etc but should be given as quantitative values e.g. p=0.032 rather than relative to 
a cut point e.g. p<0.05. 
• Generally numerical findings should not be reported to more than 1 or 2 decimal 
places. 
• The approach to carrying out any statistical modelling should be described, including 
strategies for selection of explanatory variables and goodness of fit. The models 
presented in the paper should be clearly described and justified, with appropriate 
references given. 
• Results from observational studies (cohort, case-control, or cross-sectional designs) 
should be reported following the guidelines in the STROBE statement, results of 
randomised trials should be reported following the CONSORT guidelines, and 
 
systematic reviews and meta-analyses should follow the PRISMA guidelines. 
 
 
Article publishing charges 
 
 
During submission, authors can choose to have their article published open access for 1950 
GBP (exclusive of VAT for UK and EU authors). Authors can also choose to publish their 
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article in colour for the print edition – instead of the default option of black and white – for 
250 GBP. There are no submission, page or online-only colour figure charges. 
 
For more information on open access, funder compliance and institutional programmes please 
refer to the BMJ Author Hub open access page. 
 
Submission guidelines 
 
 
Please review the below article type specifications including the required article lengths, 
illustrations, table limits and reference counts. The word count excludes the title page, 
abstract, tables, acknowledgements, contributions and references. Manuscripts should be as 
succinct as possible. 
 
For further support when making your submission please refer to the resources available on 
the BMJ Author Hub. Here you can also find general formatting guidelines across BMJ and a 
formatting checklist. 
 
 
Original research 
 
 
Authors should also provide key messages with original research submissions under the 
following headings: 
 
1. What is already known about this subject? 
 
2. What are the new findings? 
 
3. How might this impact on policy or clinical practice in the foreseeable future? 
 
 
Word count: up to 3,500 
 
Structured abstract: up to 250 words; ‘Objectives’, ‘Methods’, ‘Results’, ‘Conclusions’ 
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Tables/Illustrations: up to 5 
 
References: up to 40 
 
 
Authorship 
 
 
The ICMJE Recommendations state that authorship credit requires: 
 
 
 
Substantial contributions to the conception or design of the work, or the acquisition, analysis 
or interpretation of data. 
 
Drafting the work or revising it critically for important intellectual content. 
 
 
Final approval of the version published. 
 
 
Agreement to be accountable for all aspects of the work in ensuring that questions related to 
the accuracy or integrity of any part of the work are appropriately investigated and resolved. 
 
All of these conditions must be met. Each author should be able to identify which co-authors 
are responsible for specific other parts of the work. In addition, authors should have 
confidence in the integrity of the contributions of their co-authors. Any individuals listed as 
co-authors on a manuscript will receive email confirmation of the manuscript submission. 
 
Participation solely in the acquisition of funding, the collection of data or general supervision 
of the research group does not justify authorship. We wish authors to assure us that all 
authors included on a paper fulfil the criteria of authorship. Conversely we also ask for 
assurance that there is no one else who fulfils the criteria that has been excluded as an author. 
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Acknowledging contributors 
All contributors who do not meet the criteria for authorship should be listed in an 
Acknowledgements section. Examples of those who might be acknowledged include a person 
who provided purely technical help, writing assistance or a department chair who provided 
only general support. Financial and material support should also be acknowledged. Please 
ensure that anyone acknowledged has granted permission to be listed. 
Groups of persons who have contributed materially to the paper but whose contributions do 
not justify authorship may be listed as Collaborators, and their contribution should be 
described clearly in the contributorship statement – for example, “served as scientific 
advisors”, “critically reviewed the study proposal”, “collected data” or “ provided and cared 
for study patients”. 
As readers may infer their endorsement of the data and conclusions, all persons must give 
written permission to be acknowledged in the manuscript. 
Group authorship 
If there is a very large number of authors we may ask for confirmation that everyone listed 
met the ICMJE criteria for authorship. If they did, we may then suggest that the authors form 
a group whose name will appear in the article byline. If the author list includes a group name, 
MEDLINE will list the names of individual group members who are authors or collaborators 
(sometimes called non-author contributors) if there is a note associated with the byline clearly 
stating that the individual names are elsewhere in the paper and whether those names are 
authors or collaborators. 
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Contributorship statement 
 
 
A contributorship statement is required for every manuscript submitted and should outline 
who has contributed what to the planning, conduct, and reporting of the work described in the 
article. This should include both authors and contributors. 
 
Joint first authorship 
 
 
Joint first authors can be indicated by the inclusion of the statement ‘X and X contributed 
equally to this paper’ in the author details section of the manuscript. Further information can 
be provided in the contributorship statement if necessary. 
 
Change of affiliation 
 
 
If an author’s affiliation has changed during the course of the work, the author may either list 
the affiliation at the time that the research (or most significant portion of the research) was 
conducted, or their current affiliation, or both. For clarity, the change of affiliation can be 
explained in an acknowledgements section. 
 
Alteration to authorship 
 
 
Any change in authors after initial submission must be approved by all authors. This applies 
to additions, deletions, a change of order to the authors’ names or a change to the attribution 
of contributions. Any alterations must be explained to the Editor. The Editor may contact any 
of the authors and/or contributors to ascertain whether they have agreed to any alteration. 
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Formatting your paper 
 
 
These are general formatting guidelines across BMJ, please always refer to journal-specific 
instructions for authors for article type specifications. You can browse the titles on our 
Journals website. 
 
 
If you are looking to submit to The BMJ, please visit this section. 
 
 
 
To maximise the chances of your paper being accepted, it is a good idea to review and follow 
the formatting guidelines carefully. If your paper fits the journal’s format and article type 
specifications, busy editors and reviewers will have a much easier job at considering your 
paper, and this will save time in the long run. 
 
In order to reduce the chance of your manuscript being returned to you, please use the below 
checklist and guidelines. If you are unable to find the answer to your question, our editorial 
team will be on hand to offer assistance throughout the submission process. Contact details 
for the editorial team are on the journal’s Help page. 
 
Formatting checklist 
 
 
 
 
 
 
Author information: Have you provided details of all of your co-authors? Is the information 
 
that you have entered into ScholarOne the same as the information on the manuscript title 
page? 
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Manuscript length and formatting: Have you provided your abstract in the correct format? 
Have you supplied any required additional information for your article type, such as key 
messages? Have you checked that your manuscript doesn’t exceed the requirements for word 
count, number of tables and/or figures, and number of references? 
 
Tables: Are your tables in an editable format? Have you embedded them into the main word 
document? Have they been cited in the text? Have you provided appropriate table legends? 
Have you uploaded any lengthy tables as supplementary files for online publication? 
 
Figures: Have you uploaded figures separately from the text? Have they been supplied in an 
acceptable format and are they of sufficient quality? Are they suitable for black and white 
reproduction (unless you intend to pay any required fees for colour printing)? Have the files 
been labelled appropriately? Have the figures been cited in the text? Have you provided 
appropriate figure legends? 
 
References: Have all of the references been cited in the text? 
 
 
Supplementary files: Have you supplied these in an acceptable format? Have they been cited 
in the main text? 
 
Statements: Have you included the necessary statements relating to contributorship, 
 
competing interests and funding, data sharing, patient consent and ethical approval? 
 
 
 
Research reporting checklists: Have you either provided the appropriate statement for your 
 
study type, or explained why a checklist isn’t required? 
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Reproducing figures: Have you obtained permission from the copyright holder to re-use any 
 
previously published material? Has the source been acknowledged? 
 
 
Formatting Guidelines 
 
 
Title page 
 
 
This is excluded for the journal BMJ Quality and Safety which operates triple-blind peer 
 
review. 
 
 
The title page must contain the following information: 
 
 
Title of the article. 
 
 
Full name, postal address, e-mail and telephone number of the corresponding author. 
 
 
Full name, department, institution, city and country of all co-authors. 
 
 
Word count, excluding title page, abstract, references, figures and tables. 
 
 
 
 
 
 
Keywords 
 
 
Authors can usually opt to (or are required to) choose keywords relevant to the content of the 
manuscript during the submission process. This assists in the identification of the most 
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suitable reviewers for the manuscript. The selected keywords should also be included in the 
abstract itself. 
Manuscript format 
The manuscript must be submitted as a Word document (BMJ Case Reports and Veterinary 
Record Case Reports request that authors submit using a template which should also be in 
Word format). PDF is not accepted. 
The manuscript should be presented in the following order: 
Title page. 
Abstract, or a summary for case reports (Note: references should not be included in abstracts 
or summaries). 
Main text separated under appropriate headings and subheadings using the following 
hierarchy: BOLD CAPS, bold lower case, Plain text, Italics. 
Tables should be in Word format and placed in the main text where the table is first 
cited. Tables should also be cited in numerical order. 
Acknowledgments, Competing Interests, Funding and all other required statements. 
References. All references should be cited in the main text in numerical order. 
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Figures must be uploaded as separate files (view further details under the Figures/illustrations 
section). All figures must be cited within the main text in numerical order and legends should 
be provided at the end of the manuscript. 
Online Supplementary materials should be uploaded using the File Designation 
“Supplementary File” on the submission site and cited in the main text. 
Please remove any hidden text headers or footers from your file before submission 
Style 
Acronyms and abbreviations should be used sparingly and fully explained when first 
used. Abbreviations and symbols must be standard. SI units should be used throughout, 
except for blood pressure values which should be reported in mm Hg. 
Whenever possible, drugs should be given their approved generic name. Where a proprietary 
(brand) name is used, it should begin with a capital letter. 
Figures/illustrations 
Images must be uploaded as separate files. All images must be cited within the main text in 
numerical order and legends must be provided (ideally at the end of the manuscript). 
Video: How to improve your graphs and tables 
Colour images and charges 
Section D: Appendices 
173 
 
 
For certain journals, authors of unsolicited manuscripts that wish to publish colour figures in 
print will be charged a fee to cover the cost of printing. Refer to the specific journal’s 
instructions for authors for more information. 
 
Alternatively, authors are encouraged to supply colour illustrations for online publication and 
black and white versions for print publication. Colour publication online is offered at no 
charge, but the figure legend must not refer to the use of colours. 
 
Detailed guidance on figure preparation  
 
 
 
File types 
 
 
Figures should be submitted in TIFF or EPS format. JPEG files are acceptable in some cases. 
A minimum resolution of 300 dpi is required, except for line art which should be 1200 dpi. 
Histograms should be presented in a simple, two-dimensional format, with no background 
grid. 
 
For figures consisting of multiple images/parts, please ensure these are submitted as a single 
composite file for processing. We are unable to accept figures that are submitted as multiple 
files. 
 
During submission, ensure that the figure files are labelled with the correct File Designation 
of “Mono Image” for black and white figures and “Colour Image” for colour figures. 
 
Figures are checked using automated quality control and if they are below the minimum 
standard you will be alerted and asked to resupply them. 
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Please ensure that any specific patient/hospital details are removed or blacked out (e.g. X- 
rays, MRI scans, etc). Figures that use a black bar to obscure a patient’s identity are NOT 
accepted. 
 
Tables 
 
 
Tables should be in Word format and placed in the main text where the table is first cited. 
Tables must be cited in the main text in numerical order. Please note that tables embedded as 
Excel files within the manuscript are NOT accepted. Tables in Excel should be copied and 
pasted into the manuscript Word file. 
 
Tables should be self-explanatory and the data they contain must not be duplicated in the text 
or figures. Any tables submitted that are longer/larger than 2 pages will be published as 
online only supplementary material. 
 
Authors are responsible for the accuracy of cited references and these should be checked 
before the manuscript is submitted. 
 
Citing in the text 
 
 
References must be numbered sequentially as they appear in the text. References cited in 
figures or tables (or in their legends and footnotes) should appear at the end of the reference 
list to avoid re-numbering if tables and figures are moved around at peer review/proof stage. 
Reference numbers in the text should be inserted immediately after punctuation (with no 
word spacing)—for example,[6] not [6]. 
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Where more than one reference is cited, these should be separated by a comma, for 
example,[1, 4, 39]. For sequences of consecutive numbers, give the first and last number of 
the sequence separated by a hyphen, for example,[22-25]. References provided in this format 
are translated during the production process to superscript type, and act as hyperlinks from 
the text to the quoted references in electronic forms of the article. 
Please note that if references are not cited in order the manuscript may be returned for 
amendment before it is passed on to the Editor for review. 
Preparing the reference list 
References must be numbered consecutively in the order in which they are mentioned in the 
text. 
Only papers published or in press should be included in the reference list. Personal 
communications or unpublished data must be cited in parentheses in the text with the name(s) 
of the source(s) and the year. Authors should request permission from the source to cite 
unpublished data. 
Journals from BMJ use a slightly modified version of Vancouver referencing style (see 
example below, or download here). Note that The BMJ uses a different style. 
BMJ reference style 
List the names and initials of all authors if there are 3 or fewer; otherwise list the first 3 and 
add ‘et al.’ (The exception is the Journal of Medical Genetics, which lists all authors). Use 
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one space only between words up to the year and then no spaces. The journal title should be 
in italic and abbreviated according to the style of Medline. If the journal is not listed in 
Medline then it should be written out in full. 
Check journal abbreviations using PubMed 
Check citation information using PubMed 
Example references 
Journal article 
13 Koziol-Mclain J, Brand D, Morgan D, et al. Measuring injury risk factors: question 
reliability in a statewide sample. Inj Prev 2000;6:148–50. 
Chapter in book 
14 Nagin D. General deterrence: a review of the empirical evidence. In: Blumstein A, Cohen 
J, Nagin D, eds. Deterrence and Incapacitation: Estimating the Effects of Criminal Sanctions 
on Crime Rates. Washington, DC: National Academy of Sciences 1978:95–139. 
Book 
15 Howland J. Preventing Automobile Injury: New Findings From Evaluative Research. 
Dover, MA: Auburn House Publishing Company 1988:163–96. 
Abstract/supplement 
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16 Roxburgh J, Cooke RA, Deverall P, et al. Haemodynamic function of the carbomedics 
bileaflet prosthesis [abstract]. Br Heart J 1995;73(Suppl 2):P37. 
 
Electronic citations 
 
 
Websites are referenced with their URL and access date, and as much other information as is 
available. Access date is important as websites can be updated and URLs change. The “date 
accessed” can be later than the acceptance date of the paper, and it can be just the month 
accessed. 
 
Electronic journal articles 
 
 
Morse SS. Factors in the emergency of infectious diseases. Emerg Infect Dis 1995 Jan- 
Mar;1(1). www.cdc.gov/nciod/EID/vol1no1/morse.htm (accessed 5 Jun 1998). 
 
Electronic letters 
 
 
Bloggs J. Title of letter. Journal name Online [eLetter] Date of publication. url eg: 
Krishnamoorthy KM, Dash PK. Novel approach to transseptal puncture. Heart Online 
[eLetter] 18 September 2001. http://heart.bmj.com/cgi/eletters/86/5/e11#EL1 
 
Legal material 
 
 
Toxic substances Contro Act: Hearing on S776 Before the Subcommittee of the Environment 
of the Senate Comm. on Commerce, 94th Congress 1st September (1975). 
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Washington v Glucksberg 521 US 702 (1997) 
Law references 
The two main series of law reports, Weekly Law Reports (WLR) and All England Law 
Reports (All ER) have three volumes a year. 
For example: 
Robertson v Post Office [1974] 1 WLR 1176 
Ashcroft v Mersey Regional Health Authority [1983] 2 All ER 245 
R v Clarence [1868] 22 QBD 23 
Wimpey Construction UK Ltd v Poole (1984) Times, 3 May 
There are good historical precedents for the use of square and round brackets. Since 1891, 
round ones have referred to the date of the report, square ones to the date of publication of the 
report. Apart from not italicising the name of the case, we use the lawyers’ style; be careful 
with punctuation. Here are some more examples: 
Caparo Industries plc v Dickman and others [1990] 1 All ER 568-608. 
R v Clarence [1888] 22 QBD 23. 
Finlayson v HMAdv 1978 SLT (Notes) 60 
Block v Martin (1951) 4 DLR 121 
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Official Journal of the European Communities: at the top of the page it gives the No, vol, and 
page and, at the other side of the header, the date. 
The abbreviation for the title is given in parentheses under the title. Jiggle these elements 
around to get, eg: 
Council Directive of 14 June 1989. Offical Journal of the European Communities No L 1989 
June 28:181/44-6. (89/831/EEC. 
Digital Object Identifier (DOI) 
A DOI is a unique string created to identify a piece of intellectual property in an online 
environment and is particularly useful for articles that are published online before appearing 
in print (and therefore have not yet been assigned the traditional volume, issue and page 
number references). The DOI is a permanent identifier of all versions of an article, whether 
raw manuscript or edited proof, online or in print. Thus the DOI should ideally be included in 
the citation even if you want to cite a print version of an article. 
Find a DOI 
How to cite articles with a DOI before they have appeared in print 
Alwick K, Vronken M, de Mos T, et al. Cardiac risk factors: prospective cohort study. Ann 
Rheum DisPublished Online First: 5 February 2004. doi:10.1136/ard.2003.001234 
How to cite articles with a DOI once they have appeared in print 
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Vole P, Smith H, Brown N, et al. Treatments for malaria: randomised controlled trial. Ann 
Rheum Dis2003;327:765–8 doi:10.1136/ard.2003.001234 [published Online First: 5 February 
2002]. 
PLEASE NOTE: RESPONSIBILITY FOR THE ACCURACY AND COMPLETENESS OF 
REFERENCES RESTS ENTIRELY WITH THE AUTHOR. 
Online only supplementary material 
Additional figures and tables, methodology, raw data, etc may be published online only as 
supplementary material. If your paper exceeds the word count you should consider if any 
parts of the article could be published online only. Please note that these files will not be 
copyedited or typeset and will be published as supplied, therefore PDF files are preferred. 
All supplementary files should be uploaded using the File Designation “Supplementary File”. 
Please ensure that any supplementary files are cited within the main text of the article. 
Some journals also encourage authors to submit translated versions of their abstracts in their 
local language, which are published online only alongside the English version. These should 
be uploaded using the File Designation “Abstract in local language”. 
